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ABSTRACT 
In atherosclerosis, cholesterol accumulates in the vessel wall, mainly in the form of 
low-density lipoprotein (LDL). Macrophages of the vessel wall scavenge 
cholesterol, which leads to formation of lipid-laden foam cells. Several pathways 
and transporter proteins are involved in the regulation of cholesterol balance in 
macrophages. High plasma levels of high-density lipoprotein (HDL) protect against 
atherosclerosis, as HDL particles are able to accept cellular cholesterol and transport 
it to the liver for excretion in a process called reverse cholesterol transport. 
Phospholipid transfer protein (PLTP) remodels HDL particles in the 
circulation, generating preβ-HDL and large fused HDL particles. In addition, PLTP 
maintains plasma HDL levels by facilitating the transfer of post-lipolytic surface 
remnants of triglyceride-rich lipoproteins to HDL. Reportedly, PLTP has both 
antiatherogenic and proatherogenic properties. Most of the cholesteryl ester transfer 
protein (CETP) in plasma is bound to HDL particles and CETP is also involved in 
the remodeling of HDL particles. CETP enhances the heteroexchange of cholesteryl 
esters in HDL particles for triglycerides in LDL and very low-density lipoprotein 
(VLDL). The role of CETP in the development of atherosclerosis is controversial. 
The aim of this thesis project was to study the importance of endogenous 
PLTP in the removal of cholesterol from macrophage foam cells by using 
macrophages derived from PLTP-deficient mice, determine the effect of 
macrophage-derived PLTP on the development of atherosclerosis by using bone 
marrow transplantation, and clarify the role of the two forms of PLTP, active and 
inactive, in the removal of cholesterol from foam cells. In addition, the ability of 
CETP to protect HDL against the action of chymase in CETP-HDL complexes was 
studied. Furthermore, cholesterol efflux from macrophages derived from low- and 
high-HDL subjects was studied. Finally, cholesterol efflux potential of sera obtained 
from the study subjects was compared.  
 In this thesis project it was demonstrated that the absence of PLTP in 
macrophages derived from PLTP-deficient mice decreased cholesterol efflux 
mediated by ATP-binding cassette transporter A1 (ABCA1). The bone marrow 
transplantation studies demonstrated that selective deficiency of PLTP in 
macrophages decreased the size of atherosclerotic lesions and caused major changes 
in serum lipoprotein levels and PLTP activity. It was further demonstrated that the 
active form of PLTP can enhance cholesterol efflux from macrophage foam cells. 
Both preβ-HDL and large fused HDL particles enriched with apoE and 
phospholipids were effective in cholesterol efflux. Besides PLTP, also CETP may 
enhance the reverse cholesterol transport process, as association of CETP with 
reconstituted HDL (rHDL) particles prevented chymase-dependent proteolysis of 
discoidal rHDL and preserved their cholesterol efflux potential. Finally, monocyte 
macrophages isolated from either low- or high-HDL subjects displayed similar 
cholesterol efflux to exogenous acceptors. However, serum from high-HDL subjects 
promoted more efficient cholesterol efflux than did serum from low-HDL subjects. 
The observed difference was most probably due to differences in the distribution of 
HDL subpopulations in low-HDL and high-HDL subjects.  
The results of this thesis project indicate that both PLTP and CETP can 
remodel HDL as a cholesterol acceptor, which affects the removal of cholesterol 
from foam cells present in the vessel wall.  
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TIIVISTELMÄ 
Ateroskleroosissa verisuonten seinämiin kertyy kolesterolia LDL:n (low-density 
lipoprotein) muodossa. Verisuonten seinämän syöjäsolut eli makrofagit ottavat 
verenkierrosta kolesterolia sisäänsä ja muuttuvat kolesterolin täyttämiksi 
vaahtosoluiksi. Verisuonten seinämään kertynyttä kolesterolia voidaan poistaa 
vaahtosoluista HDL:n (high-density lipoprotein) avulla ja tähän prosessiin 
osallistuvat erilaiset lipidikuljetusproteiinit. Korkea HDL-pitoisuus verenkierrossa 
suojaa ateroskleroosilta, sillä HDL-hiukkaset pystyvät vastaanottamaan verisuonten 
seinämään kertynyttä kolesterolia ja kuljettamaan sitä maksaan elimistöstä 
poistettavaksi.  
Fosfolipidin siirtäjäproteiini (PLTP) muokkaa HDL-hiukkasia verenkierrossa 
muodostaen pieniä preβ-HDL-hiukkasia ja suuria HDL-hiukkasia. PLTP ylläpitää 
verenkierron HDL-tasoja kuljettamalla lipolyysissä muodostuneita runsaasti 
triglyseridejä sisältävien partikkelien fosfolipidijäämiä HDL-hiukkasille. 
Aikaisemmat tutkimukset ovat osoittaneet, että PLTP:llä on sekä ateroskleroosilta 
suojaavia että sitä edistäviä ominaisuuksia. Kolesteroliesterin siirtäjäproteiini 
(CETP) esiintyy verenkierrossa pääasiassa HDL-hiukkasiin liittyneenä ja osallistuu 
samalla HDL-hiukkasten muokkaukseen. CETP siirtää kolesteroliestereitä HDL-
hiukkasilta LDL- ja VLDL (very low-density lipoprotein) -hiukkasille ja 
triglyseridejä vastakkaiseen suuntaan. CETP:n merkitys ateroskleroosin 
kehittymisessä on epäselvä. 
Tämän väitöskirjatyön tavoitteena oli selvittää makrofagien tuottaman 
PLTP:n toimintaa kolesterolin poistossa vaahtosoluista PLTP-poistogeenisten hiirten 
makrofagien avulla, selvittää luuydinsiirtotekniikan avulla makrofagien tuottaman 
PLTP:n vaikutusta ateroskleroosin kehittymiseen sekä tutkia eri PLTP-muotojen, 
aktiivisen ja inaktiivisen, osuutta kolesterolin poistossa vaahtosoluista. Lisäksi 
selvitettiin CETP:n kykyä estää ateroskleroottissa leesioissa esiintyvän proteaasin, 
kymaasin, aiheuttamaa HDL-hiukkasten pilkkoutumista. Tavoitteena oli myös 
tutkia, eroaako kolesterolin poistuminen matalan ja korkean HDL-pitoisuuden 
 omaavien henkilöiden vaahtosoluista ja kuinka heidän seeruminsa toimivat 
kolesterolin vastaanottajina. 
Väitöskirjatyössä havaittiin, että PLTP:n puuttuminen poistogeenisessä 
hiirimallissa vähensi kolesterolin poistumista vaahtosoluista ABCA1-proteiinin 
välityksellä. Tutkittaessa luuydinsiirtotekniikan avulla makrofagien tuottaman 
PLTP:n merkitystä ateroskleroosin kehittymisessä havaittiin, että PLTP:n 
puuttuminen makrofageista vähensi kolesterolin kertymistä verisuonten seinämään 
ja ateroskleroottisten leesioiden kokoa sekä aiheutti huomattavia vaikutuksia 
plasman lipoproteiinien pitoisuuksiin ja PLTP-aktiivisuuteen. Väitöskirjatyössä 
havaittiin, että vain aktiivinen PLTP-muoto lisää kolesterolin poistumista 
vaahtosoluista. Aktiivisen PLTP:n muodostamat pienet preβ-HDL-hiukkaset sekä 
suuret runsaasti apoE:tä ja fosfolipidejä sisältävät HDL-hiukkaset toimivat 
tehokkaasti kolesterolin poistossa vaahtosoluista. Myös CETP saattaa lisätä 
kolesterolin takaisinvirtausta, sillä työssä osoitettiin, että CETP muodostaa 
kompleksin kiekkomaisten HDL-hiukkasten kanssa samalla suojaten näiden HDL-
hiukkasten rakennetta ja kykyä poistaa kolesterolia vaahtosoluista. Tutkittaessa 
kolesterolin poistotehokkuutta matalan ja korkean HDL-pitoisuuden omaavien 
henkilöiden vaahtosoluista kolesterolin poistotehokkuudessa ei havaittu eroa. Sen 
sijaan korkean HDL-pitoisuuden omaavien henkilöiden seerumi oli tehokkaampi 
kolesterolin vastaanottaja kuin matalan HDL-pitoisuuden omaavien henkilöiden 
seerumi. Ero kolesterolin poistotehokkuudessa johtui todennäköisesti korkean ja 
matalan HDL-pitoisuuden omaavien henkilöiden seerumien erilaisesta HDL-
hiukkasten jakaumasta.  
Tämän väitöskirjatyön tulosten perusteella voidaan todeta, että sekä PLTP 
että CETP muokkaavat kolesterolin vastaanottajahiukkasten rakennetta ja 
ominaisuuksia, mikä edelleen vaikuttaa kolesterolin poistoon vaahtosoluista 
verisuonten seinämässä.  
 
Avainsanat: ateroskleroosi, HDL, kolesterolin takaisinkuljetusjärjestelmä, 
fosfolipidin siirtäjäproteiini, kolesteroliesterin siirtäjäproteiini  
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ABBREVIATIONS 
ABCA1  adenosine triphosphate-binding cassette transporter A1 
ABCG1  adenosine triphosphate-binding cassette transporter G1 
ACAT acyl-CoA:cholesterol acyltransferase 
Apo apolipoprotein 
BPI  bactericidal permeability-increasing protein 
CAD coronary artery disease 
cAMP cyclic adenosine monophosphate 
CE cholesteryl ester 
C/EBP  CCAAT/enhancer-binding protein 
CETP cholesteryl ester transfer protein 
CHD coronary heart disease 
CM chylomicron 
CRP C-reactive protein 
CSF colony-stimulating factor 
CVD cardiovascular disease 
EL  endothelial lipase 
ELISA enzyme-linked immunosorbent assay 
FC free cholesterol 
FFA free fatty acid 
FXR farnesoid X-activated receptor 
GGE gradient gel electrophoresis 
HA-PLTP high-activity form of phospholipid transfer protein 
HDL high-density lipoprotein 
HL hepatic lipase 
ICAM-1 intercellular adhesion molecule 1 
IDL intermediate-density lipoprotein 
IL interleukin 
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IMT intima-media thickness  
INF-γ interferon-γ  
KO knockout 
LA-PLTP low-activity form of phospholipid transfer protein 
LBP lipopolysaccharide-binding protein 
LCAT lecithin:cholesterol acyltransferase 
LDL low-density lipoprotein 
LDLr  low-density lipoprotein receptor 
LPL lipoprotein lipase 
LPS lipopolysaccharide 
LT/LBP lipid transfer/lipopolysaccharide-binding protein family 
LXR liver X receptor 
MCP-1 monocyte chemotactic protein 1 
mRNA messenger ribonucleic acid 
NO nitric oxide 
PAD  peripheral arterial disease 
PAF-AH platelet-activating factor acetyl hydrolase 
PC phosphatidylcholine 
PL phospholipid 
PLTP phospholipid transfer protein 
PON paraoxonase 
PPAR peroxisome proliferator-activated receptor 
RCT reverse cholesterol transport 
rHDL reconstituted HDL 
RXR retinoid X receptor 
SAA serum amyloid A 
SMC smooth muscle cells 
SR-BI scavenger receptor class B type I 
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SREBP sterol regulatory element-binding protein 
TC total cholesterol 
TG triglyceride 
TNF-α tumour necrosis factor α  
TRL triglyceride-rich lipoprotein 
VCAM-1 vascular cell adhesion molecule 1 
VLDL very low-density lipoprotein 
WT wild-type 
WTD Western-type diet  
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1 INTRODUCTION 
Cardiovascular diseases (CVD) have been the leading cause of mortality worldwide, 
and although death rates from CVDs have declined in recent years, their prevalence 
remains high (Murray and Lopez, 1997; Hennekens, 1998; Lloyd-Jones et al., 2009). 
CVDs are an entity of diseases of the heart and vasculature, mainly caused by 
atherosclerosis. High plasma cholesterol levels have been shown to be associated 
with the increased incidence of cardiovascular diseases (Castelli et al., 1986), and 
several lipid-modifying drugs that control cholesterol biosynthesis have been 
developed. Statins, which are inhibitors of 3-hydroxy-3-methylgrutaryl coenzyme A 
(HMG-CoA) reductase introduced in the late 1980s, were the first tool for efficient 
reduction of plasma cholesterol levels (Shepherd, 2004). Statins reduce the 
availability of cellular cholesterol by inhibiting cholesterol biosynthesis and 
increasing the clearance of low-density lipoprotein (LDL) cholesterol and its 
precursors, thereby decreasing plasma cholesterol levels. Plasma LDL levels are 
further decreased when statins are combined with ezetimibe, a cholesterol-lowering 
compound that inhibits absorption of cholesterol from the small intestine. In addition 
to lowering LDL cholesterol, statins have several pleiotropic effects involving 
improvement of endothelial function and stability of atherosclerotic plaques, and 
inhibition of oxidative stress and vascular inflammation (Takemoto and Liao, 2001).  
High-density lipoprotein (HDL) protects against development of 
atherosclerosis through several mechanisms. The beneficial role of HDL was 
established already in the early 1950s (Nikkila, 1953), and after that the association 
between low levels of HDL and increased risk of CVDs has been well documented 
(Gordon et al., 1977; Kannel, 1983; Castelli et al., 1986; Jacobs et al., 1990; 
Assmann et al., 1996; Barter et al., 2007a). Furthermore, different subpopulations of 
HDL may differ in their capacity to protect against CVDs (Lamon-Fava et al., 
2008). Due to the limited benefits obtained by LDL lowering alone and the 
beneficial effects of HDL, HDL has become an interesting target of drug 
development (Linsel-Nitschke and Tall, 2005). Despite various favorable effects of 
HDL on lipid metabolism, the role of HDL in the reverse cholesterol transport 
(RCT) process is nowadays regarded the most important antiatherogenic effect of 
HDL (Fielding and Fielding, 1995; Wang and Rader, 2007). Cholesterol 
accumulation in arterial macrophages is the first hallmark of atherosclerosis, and 
membrane transporters, such as ATP-binding cassette (ABC) transporters A1 and 
G1, have an essential role in cellular cholesterol homeostasis (Pennings et al., 2006). 
Promoting RCT by affecting these membrane lipid transporters has become a 
therapeutic topic of interest (Wang and Rader, 2007).  
 15 
 
Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein 
(CETP) are two important lipid transfer proteins affecting HDL metabolism. The 
roles of PLTP and CETP in RCT are not known in detail, and both pro- and 
antiatherogenic properties have been associated with these lipid transfer proteins. 
The aim of this thesis was to clarify the function of PLTP and CETP in the removal 
of cholesterol from macrophages, the first step of the RCT process. In addition, the 
properties of macrophages and sera recovered from subjects with low or high HDL 
levels in cholesterol efflux were investigated. 
When the functions of PLTP and CETP in cellular lipid metabolism are 
known, plasma lipid levels may be pharmaceutically modified by inhibiting or 
activating the expression of these proteins in specific tissues. So far, inhibitors of 
CETP have been tested in clinical trials in an attempt to increase plasma HDL 
levels. However, in the case of PLTP, no pharmacological trials are in progress. 
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2 REVIEW OF THE LITERATURE 
2.1 ATHEROSCLEROSIS 
2.1.1 Risk factors of the disease 
Atherosclerosis is a progressive disease of the large and medium-sized arteries and 
the most important cause of heart disease and stroke in humans. Epidemiological 
studies have revealed that atherosclerosis is a multifactorial disease with several 
environmental and genetic risk factors contributing to the total risk of the disease. 
Risk factors of atherosclerosis with a strong genetic component include family 
history of atherosclerotic disease, male gender, elevated blood pressure, elevated 
levels of circulating LDL or very low-density lipoprotein (VLDL) cholesterol, 
reduced levels of circulating HDL cholesterol, diabetes, and obesity (Lusis, 2000; 
Homma, 2004). Metabolic syndrome, a cluster of metabolic disturbances including 
hypertension, high plasma triglycerides, low plasma HDL cholesterol, insulin 
resistance, and obesity, is strongly associated with the risk of atherosclerotic 
cardiovascular disease. High plasma levels of Lp(a) may also increase the risk of 
atherosclerosis, especially when associated with elevated LDL levels, although its 
role in atherogenesis remains controversial (Berglund and Ramakrishnan, 2004). 
Environmental factors associated with an increased risk of atherosclerosis and 
coronary heart disease include a high-fat diet, smoking, and lack of exercise (Lusis, 
2000). Moreover, recent reports have demonstrated that atherosclerosis is an 
inflammatory disease in which the immune system interacts with metabolic risk 
factors (Leinonen and Saikku, 2002; Esteve et al., 2005; Hansson, 2005). 
2.1.2 Development of the disease 
The vessel wall of an intact artery consists of three morphologically distinct layers, 
the intima, media, and adventitia. The intima, the innermost layer of the vessel wall 
and the site of lipid accumulation in atherosclerosis, consists of an extracellular 
connective tissue matrix covered by a monolayer of endothelial cells on the luminal 
side and separated from the media by the internal elastic lamina. The middle layer, 
the media, is a layer of smooth muscle cells (SMC) separated from the adventitia by 
the external elastic lamina, while the outer layer, the adventitia, consists of 
connective tissue, fibroblasts, and SMCs. An important event in the initiation of the 
development of an atherosclerotic lesion is endothelial dysfunction, i.e. injury of the 
endothelial cell layer at lesion-prone sites of the arteries, such as branches, 
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bifurcations, and curvatures, due to altered hemodynamic forces acting on the 
endothelial cells. The increased permeality of the damaged endothelium facilitates 
the entry of atherogenic lipoproteins such as LDL into the intima and their retention 
in the vessel wall as a result of interaction with matrix proteoglycans (Ross, 1993; 
Lusis, 2000; Rader and Daugherty, 2008). Native LDL is not taken up by 
macrophages efficiently, but oxidation, aggregation, proteolysis, or enzymatic 
modifications of LDL can increase cellular accumulation of cholesterol (Goldstein et 
al., 1979). Interaction of LDL with reactive oxygen species leads to formation of 
minimally oxidized LDL, which has proinflammatory activity. Minimally oxidized 
LDL stimulates the endothelial cells to express several proinflammatory molecules, 
including adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1), and secrete chemotactic proteins 
such as monocyte chemotactic protein 1 (MCP-1), and growth factors such as 
macrophage colony-stimulating factor (M-CSF). These molecules are involved in 
the recruitment of monocytes and lymphocytes to the artery wall, their proliferation, 
and differentiation of monocytes into macrophages (Nakashima et al., 1998; Mertens 
and Holvoet, 2001). Based on the oxidation hypothesis of atherogenesis, it is the 
oxidized LDL phospholipids generated by lipoxygenase and myeloperoxidase 
pathways that are recognized by the innate immune system (Navab et al., 2004). 
Oxidized LDL is also able to inhibit production of vasodilatating nitric oxide (NO) 
(Lusis, 2000). Following further oxidation of LDL, highly oxidized LDL forms 
aggregates that are recognized by macrophage scavenger receptors such as SR-A, 
CD36, and CD68 (Kunjathoor et al., 2002). This leads to formation of lipid-laden 
foam cells, followed by generation of a fatty streak, an early atherosclerotic lesion, 
together with T lymphocytes and SMCs (Ross, 1993). Differentiation of monocytes 
into macrophages and uptake of oxidized LDL through the scavenger receptor CD36 
are promoted by peroxisome proliferator-activated receptor γ (PPAR-γ) (Tontonoz et 
al., 1998).  
In addition to scavenger receptors, macrophages bear Toll-like receptors 
(TLR) that bind molecules such as modified lipids or heat-shock proteins (Hansson, 
2005). In contrast to scavenger receptors, Toll-like receptors can initiate activation 
of macrophages, followed by production of inflammatory cytokines, chemokines, 
proteases as well as oxygen and nitrogen radicals. Activated T cells in 
atherosclerotic lesions represent type 1 helper T (Th1) effector cells that secrete 
interferon-γ (INF-γ), which improves the efficiency of antigen presentation and 
stimulates synthesis of inflammatory cytokines tumor necrosis factor α (TNF-α) and 
interleukin-1 (IL-1). Various cytokines and growth factors produced by 
macrophages and T lymphocytes induce migration of SMCs from the media and 
their proliferation and extracellular matrix production (Lusis, 2000). SMCs increase 
retention of atherogenic lipoproteins by secreting extracellular matrix proteins such 
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as collagen and they also give rise to a fibrous cap beneath the endothelium. The 
foam cells in the atherosclerotic lesions eventually die, which leads to formation of a 
necrotic core within the plaque. Destabilization and rupture of the fibrous cap 
covering the lipid-rich core is caused by degradation of the extracellular matrix by 
proteases such as matrix metalloproteinases (MMP) and cysteine proteases including 
cathepsins (Hansson, 2005; Newby, 2005). This induces the release of thrombogenic 
material and formation of a thrombus in the lumen of the vessel, which could lead to 
myocardial infarction if the thrombus prevents blood flow through the coronary 
artery.  
2.1.3 Animal models of atherosclerosis 
Several genetically engineered mouse models have been generated to define the 
mechanisms of atherosclerosis (Breslow, 1996; Getz and Reardon, 2006). The 
mouse strains most widely used in atherosclerotic research are C57BL mice 
deficient in apolipoprotein E (apoE-/-) or low-density lipoprotein receptor (LDLr-/-) 
(Plump et al., 1992; Ishibashi et al., 1993). ApoE-/- mice are extremely prone to 
developing atherosclerotic lesions of different phases throughout the arterial tree 
when fed a chow or a Western-type fat- and cholesterol-rich diet, whereas wild-type 
mice typically develop lesions only in the proximal aorta (Nakashima et al., 1994; 
Reddick et al., 1994). The plasma lipoprotein profile of apoE-/- mice differs from 
that of humans, since most of the plasma cholesterol is carried in VLDL, while LDL 
is the major carrier of plasma cholesterol in humans (Plump et al., 1992). A mouse is 
naturally a HDL animal with low plasma levels of LDL and VLDL.  
LDLr-/- mice have been created to enhance accumulation of atherogenic 
lipoproteins in the circulation, and these mice display a lipoprotein phenotype 
similar to that seen in humans with familial hypercholesterolemia (Ishibashi et al., 
1993; Ishibashi et al., 1994). Despite the increased level of plasma LDL, LDLr-/- 
mice on a chow diet develop vascular lesions very slowly. However, their lesion 
development is markedly increased when the content of fat and cholesterol in their 
diet is increased. Furthermore, transgenic mice expressing the human apolipoprotein 
B (apoB-Tg) as well as mouse models with modified expression of various 
inflammatory or metabolic markers have been generated for use as models of 
atherosclerosis (Breslow, 1996; Ohashi et al., 2004). Development of mouse models 
has made significant advances in cardiovascular research. However, generalizations 
of results obtained from mouse studies to human physiology have to be made 
carefully, as small murines such as the mouse may not presicely reflect human 
cardiovascular physiology.   
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2.2 LIPOPROTEIN METABOLISM  
2.2.1 Lipoproteins  
Lipoproteins are water-soluble particles typically composed of a core of neutral 
lipids, mostly triglycerides (TG) and cholesteryl esters (CE), surrounded by a 
surface monolayer of amphipathic molecules, phospholipids (PL), free cholesterol 
(FC), and apolipoproteins. Five major human plasma lipoproteins are chylomicrons 
(CM), VLDL, intermediate-density lipoprotein (IDL), LDL, and HDL (Table 1) 
(Gotto et al., 1986; Betteridge, 1999). Plasma lipoproteins have been traditionally 
separated from serum by sequential ultracentrifugation at increasing solvent density 
(Havel et al., 1955). Lipoprotein classes differ in their size, density, electrophoretic 
mobility as well as in their protein and lipid composition. Lipoproteins transport 
hydrophobic TGs and cholesterol through the aqueous plasma compartment of blood 
and deliver lipids to tissues in a controlled manner. Lipoproteins are dynamic 
particles which are constantly modified in the circulation by several processes, 
including enzymatic reactions, transfer of lipids, and exchange of apolipoproteins 
(Gotto et al., 1986; Betteridge, 1999).  
The major routes involved in lipoprotein-mediated extracellular lipid 
transport, exogenous and endogenous lipid transport, and reverse cholesterol 
transport are discussed in more detail in the following chapters. 
2.2.2 Exogenous lipid transport 
The exogenous lipid transport pathway is comprised of the transport and processing 
of dietary fats and fat-soluble vitamins composed of TGs, PLs, and cholesterol. For 
absorption into enterocytes, dietary fats are first hydrolyzed into free fatty acids and 
monoacylglycerols by pancreatic lipase. Once in the enterocytes, TGs are 
resynthesized within the endoplasmic reticulum and assembled with other lipids and 
apolipoproteins into CMs for release into the lymphatic system and further into the 
circulation via the thoracic duct (Green and Glickman, 1981). CMs are large, 
heterogenous, TG-rich particles. The core of CMs consists of mainly TGs and CEs, 
while PLs, FC, apolipoproteins, and some saturated TGs are found on the surface of 
the particles (Zilversmit, 1965). The size of chylomicrons is determined by the rate 
of lipid absorption (Green and Glickman, 1981), while the fatty acid composition of 
TGs, but not the fatty acid composition of PLs in CMs, depends on the dietary fat 
composition (Kayden et al., 1963; Zilversmit, 1965; Hussain et al., 2001).  
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Apolipoprotein B-48 (apoB-48), found in CMs and CM remnants in humans, 
is synthesized by the intestine and is necessary for biosynthesis of CMs. ApoB-48 
protein is translated from the mRNA of apoB-100, which is post-transcriptionally 
modified in the intestinal cells to incorporate a stop codon (Powell et al., 1987). In 
addition to apoB-48, lymph CMs consist of several other apolipoproteins, including 
apoA-I, apoA-II, apoA-IV, apoE, and apoC synthesized in the intestine and/or liver. 
Following entry into the circulation, the apoE and apoC contents of chylomicrons 
increase as these apolipoproteins are derived from the plasma HDL fraction (Havel 
et al., 1973; Green and Glickman, 1981; Gotto et al., 1986). ApoCs have an essential 
function in the metabolism of CMs, as apoC-II functions as a cofactor required for 
activation of lipoprotein lipase (LPL), a lipolytic enzyme bound to the luminal 
surface of the capillary endothelium (Kinnunen et al., 1977; Goldberg et al., 1990). 
Core TGs of CMs as well as some surface PLs are hydrolyzed by LPL in the 
peripheral tissues, mainly in the adipose tissue and in the striated muscles, 
accompanied by the transfer of PLs to HDL. Free fatty acids (FFA) released from 
TGs are bound to plasma albumin and transported to the tissues for use as energy or 
for storage in adipose tissue (Havel, 1997).  
Hydrolysis of CMs  leads to formation of CM remnants, particles depleted  of 
TGs and enriched with CEs, which are taken up into hepatic parenchymal cells by 
receptor-mediated endocytosis through binding of apoE to a low-density lipoprotein 
receptor (LDLr) (Russell et al., 1983) or a LDL receptor-related protein (LRP) (Herz 
et al., 1988). ApoCs inhibit hepatic uptake of TG-rich lipoproteins, thus opposing 
the uptake promoted by apoE (Windler et al., 1980a; Windler et al., 1980b). ApoC, 
apoA-I, and apoA-IV as well as the PL contents of plasma CMs decrease during 
remnant formation, as these apolipoproteins are transferred to HDL (Havel et al., 
1973; Mjos et al., 1975; Tall et al., 1979), and the loss of apoC enables hepatic 
clearance of remnants. In the absence of LPL, endothelial lipase (EL) may provide 
FFAs and contribute to the subsequent uptake of FFAs to adipose tissue (Kratky et 
al., 2005). Furthermore, the composition of CM remnants is also affected by two 
circulatory lipid transfer proteins, CETP and PLTP (Tall, 1986). 
2.2.3 Endogenous lipid transport 
In addition to the exogenous origin of lipids from diet, several tissues of the human 
body are able to synthesize cholesterol and TGs. In humans, the liver is the main 
lipid-synthesizing organ, regulating plasma lipid levels and lipid homeostasis 
(Dietschy et al., 1993). Furthermore, the liver synthesizes various apolipoproteins, 
including apoA-I, apoA-II, apoB, apoC-II, apoC-III, and apoE (Zannis et al., 1981), 
which can assemble with lipids, generating lipoproteins. The endogenous lipid 
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transport pathway involves the transport of lipids from the liver to peripheral tissues. 
The liver synthesizes VLDL particles, which consist of cholesterol and TGs derived 
from both de novo synthesis and CM remnants taken up to the liver (Gibbons, 1990). 
The core of VLDL particles is rich in TGs and CEs, while the PL surface of the 
particles mainly carries apoB-100, small amounts of apoCs, apoE, and recently 
identified apoA-V (Gotto et al., 1986; O'Brien et al., 2005). ApoB-100, synthesized 
by the liver, is essential for the assembly of VLDL particles and their secretion into 
the circulation (Borchardt and Davis, 1987; Olofsson and Boren, 2005). ApoB-100 
contains hydrophobic and amphipathic sequences that probably interact with lipids 
(Olofsson et al., 1987) as well as a domain for cellular uptake of cholesterol by the 
LDLr-mediated pathway (Knott et al., 1986; Yang et al., 1986). Hepatic secretion of 
apoB was shown to be increased by cholesterol and CEs (Fuki et al., 1989; 
Cianflone et al., 1990), whereas ω-3 fatty acids decreased secretion of apoB due to 
enhanced intracellular degradation of apoB (Wang et al., 1993). 
Like CMs, VLDL particles are hydrolyzed in the circulation by LPL, 
resulting in formation of IDL particles, which can be further modified into LDL 
particles by the action of hepatic lipase (HL) (Fielding et al., 1978; Demant et al., 
1988; Demant et al., 1991). In addition to LPL, HL can cause hydrolysis of TGs in 
VLDL particles (Nicoll and Lewis, 1980). Large VLDL1 particles are catabolized 
slowly and are less efficiently converted to IDL and LDL particles than are smaller-
sized VLDL2 particles (Packard et al., 1984). It appears that apolipoproteins of 
VLDL have an important effect on VLDL metabolism, as apoC inhibits hepatic 
uptake of VLDL particles as well as small CMs (Windler and Havel, 1985). 
Furthermore, apoE polymorphisms influence the metabolism of apoB-containing 
lipoproteins, since apoE2 subjects have more highly active hepatic LDL receptors 
than apoE4 subjects and decreased conversion of VLDL to LDL (Demant et al., 
1991). During lipolysis of VLDL particles, PLTP transfers PLs to HDL particles 
(Huuskonen et al., 2001), whereas CETP mediates the exchange of TGs with CEs 
(Tall, 1993). LDL particles are transferred from the circulation to the liver and 
peripheral tissues via LDLr (Brown and Goldstein, 1986). LDLr interacts with apoB, 
which leads to internalization of the receptor-ligand complexes. Following that, the 
receptor is recycled back to the cell surface, while the LDL particle is degraded in 
the lysosomes. Released cholesterol can be re-esterified via acyl-CoA:cholesterol 
acyltransferase 2 (ACAT2) or converted into bile acids or vitamin D. The expression 
and the number of LDL receptors are regulated by the balance between the 
intracellular cholesterol content and the need for cholesterol. 
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Table 1. Properties of lipoprotein classes present in human plasma. 
 CM VLDL IDL LDL HDL2 HDL3 
Density (g/ml) 0.93 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.125 1.125-1.210 
Diameter (nm) 75-1200 30-80 25-35 18-25 9-12 5-9 
Electrophoretic 
mobility 
at origin pre-β slow pre-β β α α 
Core composition  
(mass%) 
      
TG 86 55 23 6 5 3 
CE 3 12 29 42 17 13 
Surface composition  
(mass%) 
      
FC 2 7 9 8 5 4 
PL 7 18 19 22 33 25 
   Prota 2 8 19 22 40 55 
Apolipoproteins AI, AII, AV 
B-48 
CI, CII, CIII 
E
AV 
B-100 
CI, CII, CIII 
E
 
B-100 
CI, CII, CIII 
E
 
B-100 
AI, AII 
 
CI, CII, CIII 
E
AI, AII, AV 
 
CI, CII, CIII 
E 
Source Intestine Liver VLDL VLDL/IDL Liver/ intestine 
Liver/ 
intestine 
Main function 
Transport of  
exogenous 
TG and C 
Transport of 
endogenous 
TG 
Transport of 
endogenous 
TG 
Transport of 
endogenous 
C 
Reverse 
cholesterol 
transport 
Reverse 
cholesterol 
transport 
TG, triglycerides; CE, cholesteryl ester; FC, free cholesterol; PL, phospholipids; Prot, protein; C, cholesterol. 
aProtein does not include bound carbohydrate. 
Adapted from Gotto et al., 1986; Wasan and Cassidy, 1998; Betteridge, 1999; O’Brien et al., 2005. 
 
2.2.4 Function of ATP-binding cassette transporters 
ABC transporters represent one of the largest membrane transporter families, and 
most of them are conserved in all vertebrae. ABC transporters bind and hydrolyze 
adenosine triphosphate (ATP) to generate energy for transportation of various 
molecules across the plasma membrane as well as intracellular membranes. Based 
on the sequence homology and organization of the structural domains, human ABC 
transporters are divided into seven subclasses designated from A to G. ABC 
transporters can be classified as either full transporters consisting of two 
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transmembrane domains (TM) and two cytoplasmic nucleotide-binding folds (NBF) 
or half-transporters consisting of only one TM domain and one NBF, respectively. 
To gain functionality, half-transporters must form homodimers or heterodimers with 
other half-transporters. In 2005, 48 ABC transporters were identified in humans and 
they are involved in several metabolic processes (Dean and Annilo, 2005).  
Four members of the ABC transporter family, ABCA1, ABCG1, ABCG5, 
and ABCG8, modulate lipid levels in the circulation and tissues in humans (Oram 
and Vaughan, 2006). ABCA1 mRNA is present in various human tissues, the most 
abundant expression being detected in the liver, lung, placenta, and small intestine 
(Langmann et al., 1999; Kielar et al., 2001). ABCA1 mediates the removal of PLs, 
cholesterol and other lipophilic molecules from peripheral cells to lipid-poor HDL. 
Late endosomes and lysosomes are preferential sources of cholesterol for ABCA1-
mediated cholesterol removal (Chen et al., 2001). ABCA1 has a broad substrate 
specificity for apolipoproteins of lipid-poor HDL, including apoA-I, apoA-II, apoA-
IV, apoC-I, apoC-II, apoC-III, and apoE (Remaley et al., 2001). Of note, lipid-free 
helical apolipoproteins can stabilize ABCA1 protein and prevent its degradation by 
calpain (Arakawa and Yokoyama, 2002; Wang et al., 2003a). In addition to helical 
apolipoproteins, PLTP is suggested to stabilize ABCA1 protein (Oram et al., 2003; 
Oram et al., 2008). The expression of ABCA1 is upregulated by cholesterol loading 
as well as during monocyte and adipocyte differentiation (Langmann et al., 1999; 
Kielar et al., 2001). The expression of ABCA1 induced by cholesterol loading is 
mediated through activation of the liver X receptors (LXRα and β) and the retinoid 
X receptors (RXR) (Costet et al., 2000; Schwartz et al., 2000; Venkateswaran et al., 
2000a). PPARα and PPARγ are also indirectly involved in the upregulation of 
ABCA1 expression via enhanced transcription of LXRα (Chawla et al., 2001a; 
Chinetti et al., 2001). Furthermore, factors independent of LXR/RXR, including 
membrane-permeable analogs of cyclic adenosine monophosphate (cAMP), can 
stimulate ABCA1 expression in macrophages (Oram et al., 2000). Proinflammatory 
cytokines, such as INF-γ, as well as C-reactive protein (CRP) have been reported to 
inhibit ABCA1 expression, whereas transforming growth factor-β (TGF-β) had the 
opposite effect (Panousis et al., 2001; Wang et al., 2008).  
Mutations in the gene that encodes ABCA1 lead to Tangier disease, an 
autosomal recessive disorder of lipid metabolism characterized by HDL deficiency 
syndrome, hepatosplenomegaly, and prevalent atherosclerosis (Bodzioch et al., 
1999; Brooks-Wilson et al., 1999; Rust et al., 1999). Pathophysiological hallmarks 
similar to those of Tangier disease are observed in mice with ABCA1 deficiency, 
whereas elevated plasma HDL levels are observed in mice that overexpress ABCA1, 
confirming the importance of ABCA1 in lipoprotein metabolism and HDL 
biogenesis (McNeish et al., 2000; Orso et al., 2000; Joyce et al., 2002; Wellington et 
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al., 2003). Both hepatic and extrahepatic ABCA1, especially in the intestine, are 
involved in the production of plasma HDL (Timmins et al., 2005; Brunham et al., 
2006; Singaraja et al., 2006b). Hepatic ABCA1 is also essential for catabolism of 
plasma HDL (Singaraja et al., 2006a). ABCA1 is a prerequisite for adequate 
lipidation of newly synthesized apoA-I, and lipidation of apoA-I by ABCA1 in 
hepatocytes occurs in the Golgi compartments and at the plasma membrane 
(Francone et al., 2003; Maric et al., 2005). ABCA1 also affects glucose homeostasis, 
as pancreatic ABCA1 is involved in insulin secretion from β-cells and in their 
cholesterol homeostasis (Brunham et al., 2007). Results from bone marrow 
transplantation studies have demonstrated that macrophage ABCA1 prevents 
accumulation of cholesterol into arterial macrophages, but it has only a minor 
contribution to plasma HDL levels (Haghpassand et al., 2001; van Eck et al., 2002; 
Van Eck et al., 2006).  
The ABCG family includes five characterized half-transporters (ABCG1, 
ABCG2, ABCG4, ABCG5, ABCG8), of which ABCG1 and ABCG4 are involved in 
RCT (Kusuhara and Sugiyama, 2007; Velamakanni et al., 2007). ABCG1 mRNA is 
ubiquitously expressed in human tissues, the highest expression being observed in 
the adrenal glands, lung, heart, and spleen (Klucken et al., 2000). The regulation of 
ABCG1 gene expression resembles that of ABCA1, as the expression of ABCG1 is 
induced by LXRs and PPARγ (Venkateswaran et al., 2000b; Kennedy et al., 2001; 
Li et al., 2004; Sabol et al., 2005). LXR activation induces a redistribution of 
ABCG1 from intracellular sites to the plasma membrane, which leads to enhanced 
availability and transfer of cholesterol to acceptor particles (Wang et al., 2006). Like 
ABCA1, ABCG1 is upregulated during the differentiation of monocytes into 
macrophages and during the conversion of these macrophages into foam cells 
(Klucken et al., 2000; Venkateswaran et al., 2000b). Statins reportedly down-
regulate the gene expression of both ABCA1 and ABCG1, although the clinical 
relevance of this finding is not currently known (Wong et al., 2008). In contrast to 
ABCA1, cAMP analogs do not increase the expression of ABCG1 (Suzuki et al., 
2004). Furthermore, increased expression of ABCG1 was observed in macrophages 
from patients with Tangier disease, suggesting a compensatory response in 
macrophages to the absence of the normal functioning of ABCA1 (Lorkowski et al., 
2001).  
ABCG1 and ABCG4 mediate cholesterol efflux to mature HDL2 and HDL3 
particles, but not to lipid-poor apoA-I. However, ABCG4 is mainly expressed in the 
brain and may thus play a role in brain lipid metabolism (Wang et al., 2004). 
According to the results from experiments carried out in mice with a deficiency of 
ABCG1 or mice that overexpress ABCG1, ABCG1 is essential for tissue lipid 
homeostasis (Kennedy et al., 2005). Targeted disruption of ABCG1 led to massive 
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accumulation of neutral lipids and PLs in hepatocytes and macrophages on a high-
fat diet, whereas overexpression of ABCG1 protected tissues from diet-induced lipid 
accumulation. The participation of ABCG1 in RCT and the development of 
atherosclerosis have been studied by several research groups using the bone marrow 
transplantation technique. So far, the results have been inconsistent, as bone marrow 
transplantations of ABCG1-/- bone marrow into LDLr-/- mice have indicated only a 
slightly increased or even reduced incidence of atherosclerotic lesions (Baldan et al., 
2006; Out et al., 2006; Ranalletta et al., 2006), while increased atherosclerosis was 
observed when ABCG1+/+ bone marrow was used (Basso et al., 2006). Studies on 
ABCA1/ABCG1 double knockout mice have demonstrated that the combined 
actions of ABCA1 and ABCG1 are essential to maintain lipid homeostasis in 
macrophages and to prevent foam cell formation (Out et al., 2008). 
In addition to ABCA1, another member of the ABCA family, ABCA7, 
mediates cellular PL efflux to apolipoproteins, but unlike ABCA1 it does not 
promote cellular cholesterol efflux (Wang et al., 2003b). ABCG5 and ABCG8, half-
transporters highly expressed in the liver and small intestine, control intestinal 
absorption as well as excretion of sterols from the liver to bile (Berge et al., 2000; 
Lee et al., 2001). ABCG5/ABCG8 genes are defective in sitosterolemia, a genetic 
disorder characterized by increased levels of plasma and tissue cholesterol and other 
neutral sterols. ABCG5/ABCG8 heterodimers are required for LXR-mediated 
stimulation of RCT from macrophages to feces in vivo (Calpe-Berdiel et al., 2008). 
The dual function of ABCG5/ABCG8 in the regulation of intestinal cholesterol 
absorption and biliary sterol excretion is essential for protection against 
atherosclerosis, as decreased apoB-containing lipoproteins and atherosclerosis were 
observed in mice with hepatic overexpression of ABCG5/ABCG8 only when 
cholesterol absorption from the intestine was also limited (Basso et al., 2007).  
2.2.5 Reverse cholesterol transport 
Reverse cholesterol transport is a pathway by which accumulated cholesterol is 
transported from peripheral cells to the liver and eliminated via bile into the feces 
(Fielding and Fielding, 1995; Ohashi et al., 2005). By increasing the removal of 
cholesterol from the vessel wall, RCT can prevent the development of 
atherosclerosis. The role of RCT in the active transport of cholesterol was first 
recognized by Glomset et al., who recognized that cellular FC was converted to CE 
in extracellular space by lecithin:cholesterol acyltransferace (LCAT) (Glomset, 
1968). The principal constituents of RCT are cholesterol acceptors α-HDL, preβ-
HDL, and apoA-I, enzymes LCAT and HL, lipid transfer proteins PLTP and CETP, 
transmembrane proteins ABCA1, ABCG1, and scavenger receptor BI (SR-BI) 
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(Fielding and Fielding, 2001; Ohashi et al., 2005; Tall, 2008). ApoA-I is synthesized 
by the liver and intestine and secreted into the circulation (Wu and Windmueller, 
1979). The liver and intestine are the principal sites of HDL biosynthesis, and 
hepatic and intestinal ABCA1 mediate the transfer of PLs and cholesterol to lipid-
free apoA-I, generating nascent HDL that further matures into spherical HDL 
(Timmins et al., 2005; Tsujita et al., 2005; Brunham et al., 2006). Moreover, HDL 
particles can be formed during lipolysis of TG-rich lipoproteins, as these particles 
can provide lipids and apolipoproteins for HDL (Patsch et al., 1978). HDL is present 
in several discrete subpopulations of which spherical, α-mobile HDL2 and HDL3 
present the major HDL subclasses in human plasma (Eisenberg, 1984; Barter et al., 
2003a). HDLs are the smallest, densest, and most protein-rich lipoproteins among 
the major lipoprotein classes in humans containing various apolipoproteins, 
including apoA (I, II, IV, V), apoCs, apoD, apoE, apoJ, apoL, and apoM (Xu and 
Dahlback, 1999). ApoA-I and apoA-II are most abundant in HDL. In addition, HDL 
carries several other proteins, including CETP, LCAT, PLTP, platelet-activating 
factor acetyl hydrolase (PAF-AH), serum paraoxonase-1 (PON-1), and serum 
amyloid A (SAA) (Navab et al., 1998; Van Lenten et al., 2001; Vaisar et al., 2007).  
The specific transporter proteins, ABCA1, ABCG1, and SR-BI, as well as 
aqueous diffusion, can remove cholesterol from peripheral tissues (Figure 1) 
(Yancey et al., 2003; Brewer et al., 2004; Tall, 2008). ABCA1 promotes 
unidirectional removal of PLs and cholesterol from peripheral cells onto lipid-poor 
apoA-I, generating nascent preβ-HDL besides its function in HDL formation in the 
liver and small intestine (Wang et al., 2001; Wang et al., 2004). Preβ-HDL, a small, 
discoidal, preβ-migrating lipoprotein with apoA-I as its only protein component, has 
been shown to act as a plasma recipient of cellular FC (Castro and Fielding, 1988). 
Externalized FC on the surface of nascent preβ1-HDL particles is subsequently 
esterified by LCAT, leading to generation of mature, spherical HDL3 and HDL2 
particles with CEs in their hydrophobic core (Barrans et al., 1996; Nakamura et al., 
2004; Zannis et al., 2006). In contrast to ABCA1, ABCG1 (Wang et al., 2004; 
Kennedy et al., 2005) and SR-BI (Trigatti et al., 2003) can mediate cholesterol 
efflux to mature HDL particles, but not to lipid-poor apoA-I. The relative 
importance of different efflux pathways is not known in detail and it may depend on 
cellular cholesterol status as well as the gradient of cholesterol between the cell and 
the acceptor. However, ABCA1 and ABCG1 have been shown to have an essential 
role in the removal of cholesterol from cholesterol-enriched macrophages, while SR-
BI had only a minor role in that process (Adorni et al., 2007). The essential roles of 
ABCA1 and ABCG1 in RCT have also been supported by other studies (Wang et 
al., 2007b; Yvan-Charvet et al., 2007b). Furthermore, ABCA1 and ABCG1 may act 
sequentially with ABCA1 in initiating the formation of nascent HDL particles, 
which then acquire additional lipids via the action of ABCG1 (Gelissen et al., 2006; 
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Vaughan and Oram, 2006). Cholesterol efflux via the ABCG1-mediated pathway is 
modulated by apoE and LCAT associated with HDL2 (Matsuura et al., 2006). 
Besides its role in cholesterol efflux and clearance of TG-rich lipoproteins, apoE 
participates in the biogenesis of apoE-containing HDL particles, which may 
contribute to atheroprotection (Mahley et al., 2006; Kypreos and Zannis, 2007). 
 
 
 
Figure 1. Cholesterol efflux from macrophage foam cells. 
HDL particles are continuously modified by several factors, including CETP, PLTP, 
HL, and EL, in the circulation (Wang and Briggs, 2004). In humans, CETP 
transports CEs from HDL to VLDL and LDL, and TGs in the opposite direction, 
while PLTP transfers surface PLs acquired from VLDL and CM hydrolysis by LPL 
to HDL. EL is mainly involved in PL hydrolysis, whereas HL causes hydrolysis of 
TGs and PLs of large TG-rich HDL2 particles, generating smaller HDL3 particles 
and preβ-HDL. In addition to HL, also CETP and PLTP are able to generate preβ-
HDL during remodeling of HDL particles (Barter et al., 2003a). Eventually, CEs 
from HDL are transported to the liver via SR-BI, especially in HDL mammals such 
as mice (Acton et al., 1996). In humans, CEs are removed mainly via apoB-
containing lipoproteins taken up by hepatic LDL receptors (Schwartz et al., 2004). 
In addition, a mechanism independent of hepatic SR-BI and LDLr has been 
postulated as a mediator of this uptake (Zhou et al., 2006b). Following uptake into 
the liver, cholesterol can be utilized by the cells for VLDL or HDL formation or 
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transported into bile via ABCG5 and ABCG8 (Yu et al., 2002). Lipid-poor apoA-I 
can be also catabolized via cubilin in the kidney (Kozyraki et al., 1999). 
2.2.6 Antiatherogenic properties of HDL 
Besides the essential role of HDL in RCT, it has been proposed to have anti-
inflammatory, antioxidant, antiapoptotic, antithrombotic, and vasodilatating 
properties (Barter et al., 2003a; deGoma et al., 2008; Tall, 2008). HDL is able to 
inhibit cytokine-induced expression of endothelial adhesion molecules, including 
VCAM-1, ICAM-1, and E-selectin, resulting in decreased binding of monocytes 
onto the vascular endothelium (Barter et al., 2002). Importantly, HDL can prevent 
oxidative modifications of LDL, thus reducing its atherogenicity (Van Lenten et al., 
2001). The antioxidative properties of HDL are conferred by apoA-I as well as the 
presence of other HDL-associated proteins such as PON and PAF-AH. HDL can 
provide additional antiatherogenic effects by inhibiting platelet activity and by 
inactivating coagulation factors within the coagulation cascade (deGoma et al., 
2008). The antithrombotic potential of HDL is at least partially conferred by the 
neutralizing effect of apoA-I on the procoagulant properties of anionic PLs 
(Oslakovic et al., 2009). Furthermore, upon binding to the surface of endothelial 
cells, HDL increases the activation of endothelial nitric oxide synthase (eNOS), 
leading to the release of NO, which can promote vasodilatation and reduce apoptosis 
(Tall, 2008). Finally, HDL seems to enhance endothelial repair by inducing 
endothelial progenitor cell entry into the arterial wall (Seetharam et al., 2006).  
 
 
2.3 PHOSPHOLIPID TRANSFER PROTEIN (PLTP) 
2.3.1 Characteristics of PLTP 
PLTP gene and protein 
PLTP is a member of the plasma lipid transfer/lipopolysaccharide-binding protein 
(LT/LBP) family, together with CETP, lipopolysaccharide-binding protein (LBP), 
and bactericidal permeability-increasing protein (BPI). The human PLTP gene is 
located in chromosome 20q12-q13.1 (Day et al., 1994; Whitmore et al., 1995), 
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whereas the mouse PLTP gene is localized in chromosome 2, which corresponds to 
human chromosome 20 (LeBoeuf et al., 1996). The genes for human LBP and BPI 
are encoded in close proximity to the PLTP gene in chromosome 20q11.23-q12 
(Gray et al., 1993), while the gene for CETP is located in chromosome 16q12-q21 
(Lusis et al., 1987). The genomic organization of human PLTP, LBP, and BPI is 
highly conserved and a comparison of these genes has revealed high homology with 
almost identical exon/intron junctions and exon sizes, suggesting that LBP, BPI, and 
PLTP originate from a common ancestral gene (Hubacek et al., 1997; Kirschning et 
al., 1997).  
The promoter region of the human PLTP gene consists of a TATA box, two 
GC-rich regions, and several consensus sequences for potential binding of 
transcription factors including AP-2, Sp1, CCAAT/enhancer-binding protein 
(C/EBP), IRE, NF-κΒ, XRE, MRE, AP-3, and ERE. The binding sites of 
transcription factors Sp1 (-114 to -108) and AP-2 (-94 to -85) are located within the 
area responsible for full promoter activity, and these two factors seem to be essential 
for transcription of the PLTP gene (Tu et al., 1995). The structural organizations of 
the mouse and human PLTP genes are identical. The mouse and human PLTP genes 
share an 81.1% identity within the promoter area and the consensus sequences for 
transcription factors AP-2 and Sp1 are located at the same positions. Similarities in 
the structures of the mouse and human PLTP genes suggest similar transcriptional 
regulation mechanisms of gene expression  (Tu et al., 1997a). Both mouse and 
human mature PLTP contain 476 amino acids, of which 42% are hydrophobic. 
Mouse and human PLTP share an 83% amino acid sequence identity (Albers et al., 
1995). Pig PLTP protein is 93% identical with human PLTP and 81% identical with 
mouse PLTP (Pussinen et al., 1997b). 
In human plasma, PLTP and CETP are the two key lipid transfer proteins 
responsible for the transfer of lipids between different lipoproteins. PLTP activity 
has been detected in several species, while large variation has been observed in 
CETP activities among vertebrate species (Ha and Barter, 1982; Guyard-
Dangremont et al., 1998). The homology of PLTP to CETP, LBP, and BPI has been 
shown to be 20%, 24%, and 26%, respectively (Day et al., 1994). Based on the 
structure of BPI, molecular models for LBP (Beamer et al., 1998) and PLTP have 
been constructed (Figure 2) (Huuskonen et al., 1999). The molecular model of 
PLTP suggests a boomerang-shaped, two-domain structure containing barrel-type 
structural units at each end of the protein and central β-sheets forming an interface 
between the barrels. Each domain of the PLTP molecule contains a hydrophobic 
lipid-binding pocket (Huuskonen et al., 1999). Both lipid-binding pockets are 
important in PLTP-mediated PL transfer, but the N-terminal pocket may have a 
more important role in this process. The C-terminal lipid-binding pocket may be 
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envisioned to be important for the interaction of PLTP with HDL molecules 
(Huuskonen et al., 1999; Ponsin et al., 2003). The mechanism of PLTP-mediated PL 
transfer is not known in detail. One hypothesis is that both lipid-binding pockets are 
involved in binding PL molecules to be transferred, while another hypothesis 
suggests that one lipid-binding pocket could accommodate PLs and the other 
mediates the interaction of PLTP with HDL. However, a recent report suggested that 
PLTP facilitates lipid transfer by a shuttle mechanism, and formation of a complex 
between PLTP, acceptor, and donor particles is not necessary for PL transfer (Setala 
et al., 2007).  
 
 
Figure 2. The structural model of human PLTP. The α-helixes are shown in red, the 
β-strands in yellow, and the phosphatidylcholine molecules in black (Huuskonen et 
al., 1999).  
The computed molecular mass of mature human PLTP protein is 55 kDa and of 
mouse PLTP protein, 52.7 kDa. However, the mass of human PLTP estimated by 
sodium duodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is 81 kDa. 
The discrepancy between the computed mass and the mass estimated by SDS-PAGE 
may be due to N-glycosylation, since human and pig PLTP contain 6 potential N-
glycosylation sites and mouse PLTP, 7 potential N-glycosylation sites (Day et al., 
1994; Albers et al., 1995; Pussinen et al., 1997b). N-glycosylation may be important 
for PLTP trafficking from the endoplasmic reticulum to the Golgi compartment and 
for PLTP secretion (Huuskonen et al., 1998a; Qu et al., 1999; Qu et al., 2006). 
However, when PLTP was expressed in Sf-9 insect cells synthesizing only high-
 31 
 
mannose type N-glycans, efficient secretion of fully active PLTP was observed, 
indicating that complex N-glycans are not necessary for efficient PLTP secretion or 
activity (Huuskonen et al., 1998b). The 30 C-terminal amino acids of PLTP are 
dispensable for PLTP secretion, however they are necessary for PL transfer activity  
(Huuskonen et al., 1998a). The sequence of human PLTP also contains several 
potential O-glycosylation sites (Day et al., 1994). Of the four cysteines, Cys129 and 
Cys168 are completely conserved among the members of the LT/LBP family, 
whereas Cys5 and Cys318 are found only in PLTP (Beamer et al., 1997). The 
disulphide bridge between Cys129 and Cys168 is essential for secretion of human 
PLTP, while the other cysteine residues neither participate in disulphide link 
formation nor have a dramatic effect on human PLTP synthesis and secretion 
(Huuskonen et al., 1999; Qu et al., 1999). However, Cys5 is a prerequisite for correct 
folding of pig PLTP and its secretion (Pussinen et al., 1997b). In addition to 
hydrophobic interactions, the electrostatic charge of lipoprotein particles affects the 
lipid transfer activities of PLTP and CETP (Desrumaux et al., 1998; Desrumaux et 
al., 2001) 
Regulation of PLTP gene expression  
Nuclear receptors are transcription factors that function in a ligand-activated state 
and regulate the expression of genes affecting several processes such as 
reproduction, development, and general metabolism. Adopted orphan nuclear 
receptors are one member of the nuclear receptor superfamily, and the members of 
the adopted orphan nuclear receptors include receptors of retinoic acid (RXRα,β,γ ), 
oxysterols (LXRα,β), bile acids (FXR), fatty acids (PPARα,γ,δ), and xenobiotics 
(SXR/PXR and CAR). The RXR subfamily consists of three members, RXRα, 
RXRβ, and RXRγ, which usually function as heterodimers with other nuclear 
receptors. The natural ligand of RXRs is a vitamin A derivative, 9-cis retinoic acid. 
LXRs exist in LXRα and LXRβ isoform, of which LXRα is mainly expressed in 
tissues associated with lipid metabolism, such as the liver, kidney, intestine, lung, 
adrenals, adipose tissue, and macrophages, whereas LXRβ is expressed 
ubiquitously. LXRs act as cholesterol sensors, which regulate many genes involved 
in cholesterol homeostasis and lipogenesis (Chawla et al., 2001b; Edwards et al., 
2002; Tontonoz and Mangelsdorf, 2003). Oxysterols can serve as regulators of 
cholesterol homeostasis by activating LXRs (Gill et al., 2008). Expression of the 
farnesoid X receptor (FXR) is restricted to the liver, kidney, intestine and adrenal 
gland, and bile acids, especially chenodeoxycholic acid, are physiological ligands of 
FXR (Chawla et al., 2001b; Edwards et al., 2002). PPARs exist in three isoforms, 
PPARα, PPARγ, and PPARδ. They are activated by fatty acids and eicosanoids, and 
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PPARα is regarded as a global regulator of fatty acid metabolism, while PPARγ as a 
key regulator of adipogenesis (Schoonjans et al., 1996). Lipid-lowering drugs, called 
fibrates, are ligands of PPARα (Forman et al., 1997), and antidiabetic drugs, 
thiazolidinediones, are ligands of PPARγ (Lehmann et al., 1995; Staels et al., 1997). 
PLTP expression is regulated transcriptionally by LXRs (Cao et al., 2002; 
Mak et al., 2002a; Laffitte et al., 2003), FXR (Urizar et al., 2000; Kast et al., 2001; 
Tu and Albers, 2001; Mak et al., 2002a), and PPAR (Tu and Albers, 1999; Tu and 
Albers, 2001). The PLTP gene contains two potential LXR response elements, 
DR4A and DR4B. DR4A is unable to bind LXR/RXR, but DR4B effectively binds 
LXR/RXR heterodimers. The requirement of LXR in the induction of PLTP 
expression was verified by using mice lacking both LXRα and LXRβ; the induction 
of PLTP expression by LXR and RXR ligands was completely lost in these mice 
(Laffitte et al., 2003). The DNA sequences of the human and mouse PLTP genes 
contain motifs homologous to the potential binding motifs of PPAR and FXR (Tu 
and Albers, 1999; Tu and Albers, 2001). Chenodeoxycholic acid can increase human 
PLTP promoter activity approximately 8-10-fold in the presence of the FXR-
RXRα heterodimer. This requires an IR-1 sequence in the PLTP gene promoter to 
which FXR-RXRα heterodimers specifically bind (Urizar et al., 2000). Similarly, 
chenodeoxycholic acid clearly enhances the promoter activity of the mouse PLTP 
gene (Tu and Albers, 2001). Regulation of PLTP expression differs in humans and 
mice, as fenofibrate reduces transcription of the human PLTP gene, whereas in 
mice, expression is increased (Tu and Albers, 1999; Tu and Albers, 2001). 
Simultaneous activation of LXR and PPARα causes a synergistic increase in 
liver PLTP mRNA and plasma PLTP activity levels in mice (Beyer et al., 2004). In 
addition, the PLTP gene contains potential binding sites for sterol regulatory 
element-binding protein (SREBP), C/EBP, and Sp1. SREBP proteins are inefficient 
transcriptional activators, and the presence of both SREBP and Sp1 binding sites 
close to each other in the human PLTP gene suggests that Sp1 might enhance the 
transcriptional activity of the PLTP gene, regulated by SREBP (Tu and Albers, 
1999). Earlier reports demonstrate that Sp1 and AP-2 are essential for transcription 
of the human and mouse PLTP genes (Tu et al., 1997b; Tu and Albers, 2001). 
C/EBP and PPAR have the same binding region on the PLTP gene, thus C/EBP can 
limit binding of PPAR and subsequently have an effect on the action of fibrates on 
PLTP gene expression (Tu and Albers, 1999).  
In addition to PLTP, LXR upregulates the expression of many genes involved 
in lipid and lipoprotein metabolism, including apoE (Laffitte et al., 2001; Mak et al., 
2002b), LPL (Zhang et al., 2001a), ABCG1 (Venkateswaran et al., 2000b; Kennedy 
et al., 2001), ABCG5, ABCG8 (Repa et al., 2002), ABCA1 (Costet et al., 2000; 
Schwartz et al., 2000; Venkateswaran et al., 2000a), CETP (Luo and Tall, 2000), 
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SREBP1c (Repa et al., 2000), fatty acid synthase (Joseph et al., 2002), and CYP7A 
(Lehmann et al., 1997).  
PLTP expression in tissues  
The PLTP mRNA transcript has a wide tissue distribution, suggesting important and 
various functions for the PLTP protein. In humans, PLTP expression is highest in 
the ovary, thymus, and placenta, with moderate levels in the pancreas, small 
intestine, testes, lung, and prostate. PLTP expression is moderately low in the 
kidney, liver, and spleen, and very low in the heart, colon, skeletal muscle, 
leukocytes, and brain in humans. Even though only moderate PLTP expression was 
detected in the liver, the liver as a large organ could still be a major contributor to 
plasma PLTP concentration (Day et al., 1994; Albers et al., 1995). Mouse PLTP 
expression differs clearly from that observed in humans. The highest expression of 
mouse PLTP mRNA is detected in the lung, brain, and heart, with relatively low 
levels in the liver, skeletal muscle, and testes and very low levels in the spleen and 
kidney. Expression of PLTP is very low in the mouse kidney, while the human 
kidney has moderate PLTP transcript levels (Albers et al., 1995). The tissue 
distribution of pig PLTP mRNA differs from PLTP expression in humans and mice, 
the highest levels of expression being observed in the pancreas, brain, lung, and liver 
(Pussinen et al., 1997b). PLTP mRNA is expressed in alveolar type II epithelial cells 
of the lungs of humans and mice, and its expression is induced during hypoxia and 
emphysema (Jiang et al., 1998). PLTP is also expressed in the epididymis of male 
mice and it is one factor that determines sperm motility (Drouineaud et al., 2006). 
Expression of PLTP in the ovaries, testes, prostate, and epididymis suggests that 
PLTP is important for reproduction and fertility. PLTP is also expressed in the cells 
of the central nervous system, in neurons, astrocytes, microglia, and oligodendroglia 
(Vuletic et al., 2003).  Recently, PLTP protein was detected in human tear fluid and 
it may facilitate tear PL trafficking and protect the corneal epithelium against drying 
(Jauhiainen et al., 2005).  
HA-PLTP and LA-PLTP  
PLTP exists in human plasma in two forms, one catalytically active (HA-PLTP) and 
the other inactive (LA-PLTP). The molecular mass of the active form of PLTP is 
approximately 160 kDa, while for the inactive form of PLTP, the molecular mass of 
the complex is approximately 520 kDa (Oka et al., 2000a; Karkkainen et al., 2002). 
Two forms of PLTP were also observed when human PLTP was transiently 
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expressed in mice by using the adenoviral vector (Jaari et al., 2001). In a normal 
Finnish population sample, approximately 46% of the serum PLTP concentration 
was in the catalytically active form and 54% in the inactive form (Janis et al., 2004). 
Partial characterization of PLTP particles demonstrated that HA-PLTP and LA-
PLTP are associated with lipoproteins, HA-PLTP with apoE and LA-PLTP with 
apoA-I (Karkkainen et al., 2002). PLTP secreted by HepG2 cells also associated 
with apoE but not with apoA-I, thus resembling the highly active form of human 
PLTP (Siggins et al., 2003). However, association of plasma active form of PLTP 
mainly with apoA-I-containing lipoproteins and only a little with apoE-containing 
lipoproteins has also been suggested (Cheung and Albers, 2006). The first 
hypothesis is supported by findings that PLTP is capable of interacting with apoE, 
apoA-I, and apoA-IV, of which apoE-containing proteoliposomes can activate LA-
PLTP, whereas apoA-I proteoliposomes are unable to cause activation. In addition 
to apoE proteoliposomes, also apoA-IV proteoliposomes can induce concentration-
dependent activation of LA-PLTP (Janis et al., 2005). The role of different 
apolipoproteins in the regulation of PLTP activity in vivo was further supported by 
the observation that apoE was the main determinant of circulating PLTP activity in 
type II diabetes mellitus patients (Tan et al., 2006). 
Several methods have been developed for measuring plasma PLTP activity 
(Damen et al., 1982; Jauhiainen et al., 1993; Lagrost et al., 1999) and mass 
(Desrumaux et al., 1999a; Huuskonen et al., 2000a; Oka et al., 2000b; Siggins et al., 
2004; Jauhiainen and Ehnholm, 2005). Exogenous, lipoprotein-independent PLTP 
activity (PLTPexo) is measured by the transfer of radioactively labeled PLs from 
donor liposomes to exogenously added HDL particles (Damen et al., 1982; 
Jauhiainen et al., 1993). Endogenous, lipoprotein-dependent PLTP activity 
(PLTPendo) is measured by the transfer of PLs to endogenous serum HDL (Lagrost et 
al., 1999). However, the results have been conflicting, and PLTP mass and activity 
in human plasma samples do not correlate. Only in one study was a correlation of 
plasma PLTP activity and PLTP mass demonstrated among normolipidemic study 
subjects (Desrumaux et al., 1999a). The lack of correlation might be due to the use 
of different antibodies in the mass assays and differences in the reactivities of the 
antibodies to LA-PLTP and HA-PLTP (Murdoch et al., 2002). To resolve this 
problem and to quantitate both forms of PLTP, plasma samples were first treated 
with anionic detergent SDS and after this treatment, dextran sulphate-CaCl2 
precipitation was used to separate LA-PLTP and HA-PLTP forms (Siggins et al., 
2004). In a subsample (n = 250) of the Finnish Health 2000 Examination Survey, 
considerable individual variation was observed between the relative amounts of HA-
PLTP and LA-PLTP in normolipidemic individuals (Janis et al., 2004). The 
distribution of HA-PLTP and LA-PLTP in subjects with dyslipidemia is presently 
unknown. However, based on another immunoassay, no difference in PLTP mass 
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was observed between normolipidemic subjects, type IIa hyperlipidemic patients, 
and type IIb hyperlipidemic patients (Desrumaux et al., 1999a). 
 
2.3.2 Functions of PLTP 
Phospholipid transfer 
The physiological function of PLTP and its role in lipid metabolism was discussed 
in three reviews (Huuskonen and Ehnholm, 2000; Huuskonen et al., 2001; Albers 
and Cheung, 2004). PLTP has two major functions, PL transfer and HDL 
remodeling. PLTP mediates the transfer of PLs from VLDL and CMs into HDL 
during lipolysis and exchanges PLs of VLDL and HDL (Tall et al., 1985). PLTP 
also transfers PLs from unilamellar vesicles of egg phosphatidylcholine (PC) into 
HDL (Tall et al., 1983b). PLTP transfers a number of lipids, thus PLTP is a 
nonspecific lipid transfer protein. Studies using pyrene-labeled phospholipids have 
demonstrated that PLTP is able to transfer phosphatidic acid (PA), PC, 
phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), and 
sphingomyelin (SM), but for phosphatidylethanolamine (PE) the transfer was slower 
(Huuskonen et al., 1996; Rao et al., 1997). The rate of PL transfer by PLTP is 
enhanced by unsaturation of the PC acyl chain (Rao et al., 1997), whereas an 
increase in acyl chain length decreased the rate of PL transfer. PLTP is unable to 
distinguish between positional isomers, as the position of the acyl chain, sn-1 or sn-
2, had no effect on the transfer rate (Huuskonen et al., 1996; Rao et al., 1997). 
Increased FC content of reconstituted HDL (rHDL) particles as well as decreased 
HDL particle size were shown to decrease PL transfer (Rao et al., 1997). The exact 
mechanism by which PLTP mediates PL transfer is not known in detail. PLTP does 
not form a tight complex with lipids, since no PLTP-PL intermediates were detected 
when purified PLTP was incubated with PC vesicles (Huuskonen et al., 1996). 
These findings suggest that PLTP does not act as a true lipid carrier, but instead it 
might facilitate PL transfer by forming a ternary complex between donor and 
acceptor lipoprotein particles. However, a recent report suggested that formation of a 
ternary complex between PLTP, acceptor, and donor particles is not necessary for 
PL transfer (Setala et al., 2007). The N-terminal tip of the human PLTP molecule 
contains a cluster of hydrophobic amino acids, of which Trp91, Phe92, and Phe93 are 
critical for PL transfer to HDL (Desrumaux et al., 2001). 
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Separation of PLTP and CETP has shown that the functions of these two lipid 
transfer proteins are different (Tall et al., 1983a). However, PLTP is able to increase 
CETP-mediated CE transfer from HDL3 to LDL even though PLTP itself has no 
intrinsic CE transfer activity (Lagrost et al., 1994). In addition to PLs, PLTP is able 
to transfer cholesterol from vesicles containing both PC and cholesterol to HDL3 
particles. The key function of PLTP in PL transfer is supported by the finding that 
the affinity and binding capacity of PLTP for PC are substantially higher than they 
are for cholesterol  (Nishida and Nishida, 1997).  
HDL remodeling 
In addition to PL transfer, the other major function of PLTP is HDL remodeling. 
PLTP-mediated HDL conversion remodels small HDL3 particles into larger HDL2b-
like particles, concomitantly releasing small apoA-I-containing particles, called 
preβ1-HDL (Jauhiainen et al., 1993; Tu et al., 1993). PLTP and CETP have opposite 
effects on the size distribution of plasma HDL, since PLTP can promote the 
formation of HDL2b particles at the expense of HDL3a, while CETP can increase 
formation of HDL3b particles at the expense of HDL2a (Lagrost et al., 1996). PLTP-
generated preβ-HDL particles functioned as efficient cholesterol acceptors from 
human skin fibroblasts, thus suggesting the physiological significance of PLTP-
mediated HDL remodeling (von Eckardstein et al., 1996). In addition to human 
PLTP, mouse and pig PLTP are able to convert HDL into populations of large and 
small HDL particles (Albers et al., 1995; Pussinen et al., 1995). Several mechanisms 
for PLTP-mediated HDL conversion have been suggested, but particle fusion was 
shown to be responsible for the enlargement of HDL particles observed upon 
incubation with PLTP (Lusa et al., 1996; Korhonen et al., 1998). Further studies 
have suggested that the initial event of HDL remodeling by PLTP involves a large, 
unstable fusion product with six apoA-I molecules. Then, the fusion product 
rearranges into three small particles, each containing two apoA-I molecules, or two 
molecules of apoA-I dissociate from the fusion product, concomitantly forming a 
large particle with four molecules of apoA-I (Settasatian et al., 2001). Mutations of 
hydrophobic residues at the surface of the human PLTP molecule were shown to 
impair HDL remodeling (Desrumaux et al., 2001). Furthermore, PLTP can also 
remodel HDL2 particles, simultaneously generating preβ-HDL particles (Marques-
Vidal et al., 1997).  
The two main functions of PLTP have a causal relationship, since efficient 
PLTP-mediated HDL conversion is dependent on efficient PL transfer (Huuskonen 
et al., 2000b). Only a small increase in HDL particle size can occur in the absence of 
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apoA-I release, but continuation of the process with the release of apoA-I requires 
efficient PL transfer by PLTP. PLTP-mediated HDL conversion requires the 
presence of apoA-I, as demonstrated by the inability of human plasma PLTP to 
remodel rHDL particles containing apoA-II as a sole protein component (Lusa et al., 
1996). Furthermore, the increased apoA-II/apoA-I molar ratio in HDL particles 
inhibits PLTP-mediated HDL interconversion (Pussinen et al., 1997a). PLTP also 
remodels spherical, apoE-containing rHDL particles into large and small particles 
via a series of particle fusions and structural rearrangements without concomitant 
dissociation of lipid-free or lipid-poor apoE (Settasatian et al., 2008). The steps of 
remodeling of apoE-containing particles differ from those reported for apoA-I-
containing particles, which involve a single particle fusion and a rearrangement of 
the fusion product or release of lipid-free or lipid-poor apoA-I (Lusa et al., 1996; 
Korhonen et al., 1998; Settasatian et al., 2001; Settasatian et al., 2008). PLTP-
mediated remodeling of apoE-containing rHDL is more extensive than that of apoA-
I-containing rHDL, but apoE reduces the capacity of PL transfer by PLTP compared 
with apoA-I in HDL particles (Settasatian et al., 2008). Increased TG content of 
HDL particles promotes PLTP-mediated remodeling (Rye et al., 1998; Settasatian et 
al., 2001), which may be due to destabilization of apoA-I in TG-rich HDL particles 
(Settasatian et al., 2001).  
PLTP is also able to remodel HDL during an acute-phase reaction, as PLTP-
facilitated conversion of HDL enriched with SAA was more effective than 
conversion of native HDL3, despite decreased apoA-I concentration (Pussinen et al., 
2001). However, PLTP-mediated degradation of apoA-I in SAA-enriched HDL was 
accelerated compared with that of native HDL, which might be associated with the 
decreased levels of HDL seen during inflammation. Oxidative modifications of 
HDL3 and TG-rich HDL3 impair the substrate properties of the particles, decreasing 
PLTP-mediated HDL conversion (Pussinen et al., 2003). 
Other functions of PLTP 
In addition to PLs, PLTP is able to transfer LPS (Hailman et al., 1996) and α-
tocopherol (Kostner et al., 1995). PLTP was found to be able to bind and neutralize 
LPS, exchange LPS between micelles, and transfer LPS to rHDL particles (Hailman 
et al., 1996) and from HDL particles to LDL particles (Levels et al., 2005). The 
transfer of LPS from HDL to LDL particles causes a generation of two 
subpopulations of HDL particles, which may contribute to the dyslipidemia seen 
during the acute-phase response to infection (Levels et al., 2005). PLTP may also 
extract LPS from bacterial membranes before its transfer to HDL (Vesy et al., 2000). 
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A high concentration of PLTP in the blood may diminish inflammatory responses to 
LPS, since addition of recombinant PLTP inhibited the ability of LPS to stimulate 
cytokine production in blood (Hailman et al., 1996). Whether the neutralizing effect 
of recombinant PLTP was due to neutralization by binding LPS or by transfer of 
LPS to lipoproteins was not clarified. LPS and dietary cholesterol regulate PLTP 
expression in opposite directions in mice, as LPS injection decreased both plasma 
PLTP activity and mRNA expression, whereas a high-fat, high-cholesterol diet 
increased them (Jiang and Bruce, 1995). However, PLTP was unable to transfer LPS 
to CD14, thus it does not mediate cellular responses to LPS (Hailman et al., 1996). 
Just recently, the role of PLTP in the prevention of endotoxic shock was 
demonstrated by a study showing that LPS-induced mortality was increased in mice 
with PLTP deficiency (Gautier et al., 2008). 
α-tocopherol, a potent antioxidant form of vitamin E, is transported by 
plasma lipoproteins, and besides its antioxidant function, it plays an important role 
in several cell functions such as cell signaling and gene expression (Traber and 
Packer, 1995). PLTP catalyses the transfer of α-tocopherol to HDL particles and the 
exchange between different lipoprotein classes (Kostner et al., 1995). PLTP 
promotes net movement of α-tocopherol from HDL particles to oxidized LDL 
particles and to endothelial cells (Desrumaux et al., 1999b). Thus, PLTP-mediated 
α-tocopherol transfer may have at least two antiatherogenic functions by providing 
LDL with antioxidant and by preserving the normal relaxing function of endothelial 
cells in the vessel wall. Recent results indicate that α-tocopherol transfer is mediated 
by multiple mechanisms, since not only PLTP, but also CETP transfers α-tocopherol 
to lipoproteins (Hacquebard et al., 2008). Macrophage PLTP deficiency was shown 
to cause a significant decrease in α-tocopherol content together with increased 
oxidative stress in bone marrow cells (Valenta et al., 2006b), while dietary α-
tocopherol supplementation led to a significant decrease in cholesterol accumulation 
in macrophages from  PLTP-deficient mice (Ogier et al., 2007). 
In addition, PLTP is capable of causing proteolytic cleavage of apoA-I 
(Jauhiainen et al., 1999). Cleavage of apoA-I occurs in the C-terminal portion of 
apoA-I between the amino acids Ala196 and Thr197. Furthermore, plasma PLTP 
activity was shown to be the major determinant of LpA-I, but not LpA-I:A-II, 
kinetics in men, and it may contribute to maintenance of the plasma concentrations 
of these lipoproteins in different hypercatabolic conditions of HDL particles (Ooi et 
al., 2006). PLTP may also affect the plasma distribution of amphotericin B, a 
polyene macrolide antibiotic used in the treatment of systemic fungal infections 
(Patankar and Wasan, 2006). Recently, the involvement of PLTP in apoptosis of 
macrophages was reported (Wehinger et al., 2007).  
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Cholesterol efflux 
Besides its functions in PL transfer and HDL remodeling, increasing evidence points 
to a function for PLTP in the removal of cholesterol and PLs from peripheral cells. 
PLTP treatment of a plasma sample was shown to cause a significant increase in 
preβ-HDL formation and cholesterol efflux from human skin fibroblasts (von 
Eckardstein et al., 1996). Furthermore, plasma PLTP activity was positively 
correlated to cholesterol efflux from Fu5AH hepatoma cells (Syvanne et al., 1996). 
The role of PLTP in cholesterol efflux was also supported by findings that efflux 
from Fu5AH cells to plasma from insulin-resistant subjects was not impaired, which 
may be related to higher plasma PLTP activity and enhanced preβ-HDL formation 
(Dullaart and van Tol, 2001). The capability of plasma PLTP and CETP to generate 
preβ-HDL was evaluated using plasma samples from human PLTP transgenic mice 
(huPLTPtg), human CETP transgenic mice (huCETPtg), and mice transgenic for 
both (huPLTPtg/huCETPtg) (Lie et al., 2001). Based on the results, the ability of 
PLTP to generate preβ-HDL is more efficient than that of CETP, thus supporting the 
role of PLTP in RCT. Mast cells in human atherosclerotic lesions contain a neutral 
protease chymase, which degrades PLTP and preβ-HDL generated by PLTP, and 
impairs cholesterol efflux from foam cells (Lee et al., 2003).  
PLTP increased PL and cholesterol efflux from cholesterol-loaded human 
skin fibroblasts to HDL, but not to bovine serum albumin or apoA-I (Wolfbauer et 
al., 1999). The enhanced lipid efflux was shown to be due to the ability of PLTP to 
enhance binding of HDL to the cell surfaces, which may improve remodeling of 
HDL particles, thus increasing their ability to remove PLs and cholesterol by the 
apolipoprotein-mediated pathway. PLTP-stimulated lipid efflux was absent in 
fibroblasts derived from Tangier disease patients, suggesting that PLTP enhanced 
lipid efflux by an ABCA1-dependent mechanism. The connection between ABCA1-
mediated lipid removal and PLTP was confirmed using murine macrophages with 
induced ABCA1 expression and ABCA1-transfected baby hamster kidney (BHK) 
cells (Oram et al., 2003). The results demonstrated that when ABCA1 was induced, 
PLTP alone increased removal of cholesterol and promoted cholesterol and PL 
efflux to HDL. In addition, both PLTP and apoA-I covalently cross-linked to 
ABCA1 at the same or closely related sites and stabilized ABCA1 protein. Further 
studies have demonstrated that amino acids 144-163, located at the tip of the N-
terminal barrel of the PLTP molecule, are critical for ABCA1-mediated cholesterol 
efflux, stabilization of ABCA1 protein, and interaction with PLs and PL transfer 
(Oram et al., 2008). In contrast, PLTP showed no effect on cholesterol efflux in 
three studies (Cao et al., 2002; Valenta et al., 2006b; van Haperen et al., 2008) in 
which thioglycollate-elicited peritoneal macrophages from PLTP-deficient mice, 
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mice deficient in macrophage PLTP, and huPLTPtg/tg mice were used. However, 
thioglycollate treatment of mice induces an inflammatory reaction, which may 
modulate the results (Cook et al., 2003). 
Recently, enhanced cholesterol efflux from cultured fibroblasts to plasma 
from hypertriglyceridemic type II diabetic patients was observed, and it was 
associated with increased PLTP activity and cholesterol esterification (de Vries et 
al., 2008). Preβ-HDL levels and preβ-HDL formation were unaltered in diabetic 
hypertriglyceridemia, which could contribute to maintenance of functional 
cholesterol efflux. A recent report demonstrated that heavy alcohol drinkers had 
increased plasma PLTP activity and decreased CETP activity, which may partly 
explain the increased amount  of  HDL2b particles and increased HDL2 PLs as well as 
enhanced cholesterol  efflux to HDL2 compared with controls (Makela et al., 2008). 
However, in one study, increased plasma PLTP activity and decreased cholesterol 
efflux were observed in type II diabetic patients with or without coronary artery 
disease (Attia et al., 2007).  
 
2.3.3 PLTP and atherosclerosis 
The function of PLTP in the accumulation or removal of cholesterol to/from the 
arterial wall was supported by the presence of PLTP protein in macrophages of 
human atherosclerotic lesions (Desrumaux et al., 2003; Laffitte et al., 2003; O'Brien 
et al., 2003), whereas only a minimal amount of PLTP was detected in 
nonatherosclerotic coronary arteries (O'Brien et al., 2003). PLTP gene expression 
gradually increased during macrophage differentiation, and differentiated 
macrophages were able to produce and secrete PLTP (Desrumaux et al., 2003). 
Cholesterol loading of macrophages increased PLTP mRNA levels, PLTP protein 
expression, and its activity (Desrumaux et al., 2003; O'Brien et al., 2003). 
Observations that extracellular PLTP and apolipoproteins colocalized with the 
extracellular matrix proteoglycan biglycan, and that active and inactive PLTP 
increased HDL binding to biglycan, suggest that PLTP may mediate lipoprotein 
binding to proteoglycans independent of its PL transfer activity (O'Brien et al., 
2003). PLTP protein was also present in the necrotic cores of atherosclerotic lesions, 
while biglycans were not, which may be due to degradation of extracellular matrix 
biglycan by specific matrix metalloproteinases in the necrotic cores.  
Plasma PLTP activity was found to be an independent risk factor of coronary 
artery disease (CAD) in patients with stable or unstable angina pectoris or recent 
acute myocardial infarction (Schlitt et al., 2003). Patients within the highest quintile 
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of PLTP activity had a 1.9-fold increased risk of CAD compared with patients in the 
lowest quintile. The authors suggested that high plasma PLTP activity may decrease 
HDL concentration and increase the concentration of TG-rich lipoproteins, both of 
which are well-known risk factors of CAD. Furthermore, high PLTP activity may 
provide a pro-oxidant stage, and it may transfer more oxidized PLs from TG-rich 
lipoproteins to HDL. In a recent study, high plasma PLTP activity was associated 
with fatal and nonfatal cardiovascular events in CAD patients under statin treatment, 
although the underlying mechanism was not presented by the authors (Schlitt et al., 
2009). The atherogenic role of PLTP was further supported by the observation that 
high plasma PLTP activity is associated with increased intima-media thickness 
(IMT) in type II diabetic patients (de Vries et al., 2006). Another study demonstrated 
that PLTP activity was significantly decreased in patients with peripheral arterial 
disease (PAD), while PLTP mass did not differ between PAD patients and controls 
(Schgoer et al., 2008). These results indicate that in non-diabetic, non-smoking 
subjects, low rather than high PLTP activity is a marker for the presence of PAD, 
and the distribution of PLTP between low-activity and high-activity forms is 
disturbed. PLTP activity was shown to associate positively with plasma CRP and 
SAA levels in patients with low HDL and CVD, a state of chronic inflammation 
(Cheung et al., 2006). On the other hand, serum PLTP mass was shown to be a 
possible protective factor of coronary heart disease in a cohort of Japanese men, 
although no association between serum PLTP concentration and risk of stroke was 
observed (Yatsuya et al., 2004).  
 
2.3.4 Mouse models of atherosclerosis with modified PLTP expression 
PLTP knockout mice 
The physiological importance of PLTP in vivo has been demonstrated in PLTP 
knockout (PLTP-KO or PLTP-/-) mice (Jiang et al., 1999). Complete loss of PL 
transfer activity in vitro and in vivo as well as partial loss of FC transfer activity 
were observed in the plasma of PLTP-KO mice. HDL PL, cholesterol, and apoA-I 
were significantly decreased in PLTP-KO animals on a chow diet. On a high-fat 
diet, HDL levels were similarly decreased, while VLDL and LDL PLs, FC, and  CEs 
were increased without changes in apoB levels. These results suggest that the 
surface components of TG-rich lipoproteins accumulate in the absence of PLTP-
mediated transfer to HDL particles. The lamellar lipoproteins accumulating in the 
PLTP-KO mice were found to be enriched in PLs, FC, apoA-IV, and apoE (Qin et 
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al., 2000). In these animals, increased catabolism of HDL protein as well as CEs was 
observed, a condition that can lead to hypoalphalipoproteinemia. When CETP-
transgenic mice were crossed into a PLTP-KO background, the expression of CETP 
could not compensate the low-HDL phenotype, and in fact the phenotypes were 
additive, leading to markedly decreased HDL (Kawano et al., 2000). Further studies 
have demonstrated that SR-BI and HL are involved in the clearance of PL- and FC-
rich particles in PLTP-KO mice, although dietary factors can influence clearance 
(Kawano et al., 2002).  
To study the effect of PLTP deficiency on dyslipidemia and atherosclerosis, 
PLTP-KO mice were crossed into apoB-Tg, apoE-/-, or LDLr-/- backgrounds (Jiang 
et al., 2001). In all three mouse models, PLTP deficiency resulted in markedly 
decreased atherosclerosis. Decreased levels of apoB-containing lipoproteins were 
observed in apoB-Tg/PLTP-/- and apoE/PLTP-/- mice, with reduced levels of CEs, 
FC, PLs, and TGs in VLDL and LDL, suggesting the involvement of PLTP in the 
regulation of plasma levels of apoB-containing lipoproteins in these animals. This 
was accompanied by diminished secretion of apoB-100 and apoB-48 from the 
hepatocytes of the apoB-Tg/PLTP-/- mice compared with the apoB-Tg controls. 
Instead, PLTP deficiency showed no significant effects on the levels of apoB-
containing lipoproteins in LDLr-/- mice, indicating the role of LDLr in reducing 
plasma VLDL and LDL levels in PLTP-KO mice. PLTP deficiency was shown to 
increase the α-tocopherol content of VLDL and LDL, thus decreasing the 
susceptibility of these lipoproteins to oxidation (Jiang et al., 2002). Further studies 
have demonstrated that the α-tocopherol content in the liver was diminished, the 
content of lipid peroxides in hepatocytes was increased, and ROS-dependent 
destruction of newly synthesized apoB-100 was enhanced in PLTP-KO mice (Jiang 
et al., 2005). Vitamin E supplementation decreased the cellular lipid peroxide 
content and ROS activation and normalized the production of apoB. 
PLTP deficiency was shown to improve the anti-inflammatory properties of 
HDL and reduce LDL-induced monocyte chemotactic activity (Yan et al., 2004). 
The anti-inflammatory role of PLTP deficiency was further supported by findings 
that PLTP-KO mice had significantly lower IL-6 levels compared with control 
animals (Schlitt et al., 2005). PLTP deficiency was also associated with decreased 
cholesterol uptake and secretion by enterocytes without any significant effect on the 
uptake and secretion of fatty acids (Liu et al., 2007b). Niemann-Pick C1-like 1 
mRNA levels were decreased in the small intestine of PLTP-KO mice, which could 
decrease the uptake of cholesterol. Additionally, the mRNA level of ABCA1 and 
microsomal triglyceride transfer protein (MTP) activity were decreased in the small 
intestine of PLTP-KO mice, possibly contributing to lower secretion of cholesterol. 
Thus, decreased cholesterol absorption could be one mechanism causing low 
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cholesterol levels and decreased atherosclerosis in PLTP-KO mice. PLTP deficiency 
was shown to alter hepatic lipid status, decreasing PL species containing long-chain 
fatty acids and increasing PL species containing medium-chain mono- or di-
unsaturated fatty acids (Siggins et al., 2007). This was associated with secretion of 
apoA-I with a lower PL content and reduced stability from hepatocytes. 
Overexpression of PLTP 
Human PLTP transgenic (huPLTPtg) mice were established in 1996 (Albers et al., 
1996; Jiang et al., 1996). PLTP activity levels as well as their effects on lipoprotein 
and apolipoprotein levels have been variable. When huPLTPtg mice were cross-bred 
with human apoA-I transgenic (huApoA-Itg) mice, increased PLTP activity (~50%) 
was accompanied by a remarkable increase in preβ-HDL and a small increase in α-
HDL (Jiang et al., 1996). Further studies of huPLTPtg mice showing a 2.5-4.5-fold 
increase in PLTP activity have demonstrated a significant reduction in plasma HDL 
levels (van Haperen et al., 2000). However, formation of preβ-HDL was increased 
2-3-fold in huPLTPtg mice. Thus, despite lower total HDL levels, PLTP can act as 
an antiatherogenic factor that prevents cholesterol accumulation. Adenovirus-
mediated overexpression of PLTP in wild-type C57BL mice and in huApoA-Itg 
mice led to a 2.5-40-fold increase in plasma PLTP activity levels as well as a 
significant reduction in serum cholesterol, PLs, and TGs as well as increased preβ-
HDL levels (Foger et al., 1997; Ehnholm et al., 1998). Plasma apoA-I concentration 
was clearly reduced in these animals due to the accelerated rate of fractional 
catabolism of HDL particles, which caused a substantial decrease in HDL levels. 
Similar changes in plasma lipids and lipoproteins were observed in a study using 
mice with transient adenovirus-mediated overexpression of human PLTP (Jaari et 
al., 2001). The distributions of PLTP activity and mass in serum were shown to be 
different, which suggested the presence of two forms of PLTP, one with high and 
the other with low PL transfer activity. PLTP overexpression enhanced hepatic 
uptake of CEs and PLs from HDL (Foger et al., 1997). In another study, a high 
overexpression of PLTP (15-fold) caused rapid clearance of HDL from the 
circulation and a 1.8-fold increase in hepatic CEs (Post et al., 2003). This led to a 2-
fold increase in bile acid secretion and a 1.4-fold increase in the amount of excreted 
fecal bile acids, demonstrating the beneficial effect of PLTP on cholesterol removal 
from the body. To further characterize the role of PLTP in lipid metabolism, mice 
with inducible but reversible overexpression of PLTP were generated (Moerland et 
al., 2007a). An inducible mouse model provides stable and easily controlled PLTP 
overexpression, which differs from the transient induction obtained with an 
adenoviral expression system. Upon induction of PLTP expression, decreased 
 44 
 
plasma cholesterol and PLs as well as decreased HDL cholesterol and PLs were 
observed.  
The effect of PLTP overexpression on VLDL secretion was studied by 
overexpressing PLTP in mice heterozygous for LDLr (LDLr+/- mice) (van Haperen 
et al., 2002). Multiorgan and hepatic overexpression of PLTP caused a ~1.5-fold 
increase in VLDL secretion as well as a dose-dependent increase in susceptibility to 
atherosclerosis. When VLDL secretion was studied in huCETPtg and 
huCETPtg/huPLTPtg mice in a C57BL background, a similar 1.5-fold increase in 
VLDL secretion caused by PLTP overexpression without changes in the 
composition of VLDL particles was observed (Lie et al., 2002). PLTP 
overexpression in apoE-/- mice using an adenovirus-associated virus-mediated 
system caused an increase in plasma PLTP activity and decreased α-tocopherol 
content in plasma and lipoproteins (Yang et al., 2003). The results indicate that 
PLTP represents a factor that determines vitamin E content and oxidizability of 
lipoproteins, thus suggesting a proatherogenic role for PLTP. The proatherogenic 
role of systemic PLTP activity was further supported in several mice studies (Lie et 
al., 2004; Moerland et al., 2007b; Moerland et al., 2008).  
Bone marrow transplantation studies 
Recently, the effect of macrophage-derived PLTP on the development of 
atherosclerosis was studied using the bone marrow transplantation technique 
(Valenta et al., 2006b; Valenta et al., 2008). In both studies, macrophage-derived 
PLTP was shown to be atheroprotective, as increased atherosclerosis was observed 
in mice deficient in macrophage PLTP, whereas atherosclerotic lesions were 
significantly smaller in mice expressing PLTP only in hematopoietic cells. PLTP 
deficiency also decreased α-tocopherol content and increased oxidative stress in 
bone marrow cells (Valenta et al., 2006b). However, overexpression of human 
apoA-I was shown to provide substantial and sustained atheroprotection in LDLr-/- 
mice (Valenta et al., 2006a; Valenta et al., 2006b). Macrophage PLTP deficiency 
can reduce apoE secretion from macrophages, which may promote accumulation of 
cholesterol in the circulation and eventually the vessel wall (Liu et al., 2007a). A 
proatherogenic role for macrophage PLTP has also been suggested (van Haperen et 
al., 2008). 
The results from bone marrow transplantation studies suggest that the effects 
of systemic PLTP on lipid metabolism and development of atherosclerosis are 
considerably different from those of PLTP expressed locally in tissues (Valenta et 
al., 2006b; Valenta et al., 2008). PLTP produced locally by macrophages within the 
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vessel intima may accelerate RCT by improving local generation of preβ-HDL 
particles without affecting plasma preβ-HDL levels, or it can stabilize ABCA1 and 
increase ABCA1-mediated cholesterol efflux, whereas the effect of systemic PLTP 
is mainly proatherogenic. The hypothesis of the differential role of systemic and 
macrophage PLTP was also supported by another research group using PLTP 
transgenic mice, which demonstrated that higher systemic PLTP levels may promote 
development of atherosclerosis by decreasing the rate of macrophage RCT (Samyn 
et al., 2008). 
Mouse models have increased our knowledge about the function of PLTP in 
lipid and lipoprotein metabolism as well as in atherogenesis. However, PLTP levels 
in mice that overexpress PLTP and in PLTP-KO mice are nonphysiological and very 
different from those observed in humans. PLTP deficiency does not exist in humans, 
but increased PLTP levels are seen in humans with type I or type II diabetes and 
obesity, although the increase in PLTP activity in these conditions is moderate. 
Thus, dramatic alterations in PLTP activity may modulate the results and complicate 
generalization of the results to human pathophysiology (Tall and Lalanne, 2003). 
 
 
2.4 CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) 
2.4.1 Characteristics of CETP 
CETP gene and its regulation 
The human CETP gene exists as a single copy in chromosome 16q12-16q21 (Lusis 
et al., 1987) and consists of 16 exons, encompassing about 25 kb of genomic DNA 
(Agellon et al., 1990). CETP, originally called lipid transfer protein I (LTP-I), was 
isolated from human plasma and separated from PLTP, originally called LTP-II 
(Tall et al., 1983a; Albers et al., 1984; Tollefson et al., 1988), in the 1980s. CETP 
activity is observed in various vertebrate species. However, considerable variation in 
activities is reported among different vertebrate species (Ha and Barter, 1982; 
Guyard-Dangremont et al., 1998). No CETP activity has been observed in mice, 
which are widely used in atherosclerotic research. Rabbit and hamster CETP share 
an overall sequence homology of approximately 80% with human CETP at the 
amino acid level (Drayna et al., 1987; Nagashima et al., 1988; Jiang et al., 1991). 
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The CETP gene is expressed at high levels in adipose tissue, the heart, and 
skeletal muscle and at lower levels in many other tissues in several mammalian 
species, while in humans, high levels of CETP expression are found in adipose 
tissue and the liver (Jiang et al., 1991). CETP is capable of enhancing selective 
uptake of CEs from HDL by human adipocytes, suggesting that this pathway may 
have an effect on HDL remodeling and adipocyte cholesterol accumulation (Benoist 
et al., 1997). In agreement with these findings and hypothesis, the expression of 
CETP in adipose tissue was shown to have a significant contribution to circulatory 
CETP mass and activity and to cause a reduction in HDL and an increase in non-
HDL cholesterol levels (Zhou et al., 2006a). A high-cholesterol diet and increased 
cellular cholesterol content upregulate CETP mRNA levels and increase plasma 
CETP activity (Quinet et al., 1990; Jiang et al., 1991; Jiang et al., 1992; Oliveira et 
al., 1996). Regulation of CETP promoter activity involves LXRs and SREBPs. Both 
LXRα/RXRα and LXRβ/RXRα activate the CETP promoter via its DR4 element in 
a sterol-responsive fashion, while SREBP-1a and SREBP-2 activate the CETP 
promoter via interaction with its cholesterol response element (CRE) (Gauthier et 
al., 1999; Luo and Tall, 2000). Additionally, the human CETP gene promoter 
contains binding sites for several transcription factors that regulate its activity, such 
as ARP-1, YY-1, C/EBP, and Sp1 (Bruce et al., 1998b).  
Structure of CETP protein 
Mature human CETP protein comprises 476 amino acids. The translated molecular 
mass of CETP is 53 kDa, but the mass estimated by SDS-PAGE is 74 kDa (Drayna 
et al., 1987). CETP protein contains four potential asparagine-linked glycosylation 
sites at residues 88, 240, 341 and 396, and glycosylation of the protein can cause the 
discrepancy between the translated molecular mass and the mass estimated by SDS-
PAGE. Based on sequence analysis, CETP is an extremely hydrophobic protein. The 
previous model of CETP was based on the crystal structure of BPI. However, as the 
amino acid identity of human CETP and BPI is only 22%, the accuracy of the model 
was not comprehensive (Bruce et al., 1998a).  
The crystal structure of CETP was solved in 2007 (Figure 3) (Qiu et al., 
2007). Based on that model, CETP is an elongated boomerang-shaped molecule. 
The structure of CETP is divided into four structural units, barrel C at the C-terminal 
end of the protein, barrel N at the N-terminal end, a central β-sheet between the two 
barrels and a C-terminal extension. The N- and C-terminal barrels as well as the 
central β-sheet are also found in BPI, but the C-terminal extension is not present in 
BPI (Beamer et al., 1997; Beamer, 2003). The terminal barrels of the CETP and BPI 
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molecules include a highly twisted β-sheet and two helices (Beamer et al., 1997; 
Beamer, 2003; Qiu et al., 2007). The central β-sheet of CETP was shown to contain 
six antiparallel strands, including residues from both the N- and C-terminal domains 
(Qiu et al., 2007). The structural unit unique to CETP, helix X, consisting of 
residues 465-476 at the C-terminal end of the CETP molecule, forms a distorted 
amphipathic helix that unwinds slightly at the end. The three structural units of 
CETP overlay well with the homologous units of BPI, and the crystal structure of 
CETP confirms the folds of the structural units of the molecule predicted earlier. 
However, the relative orientations of the structural units of CETP differ, resulting 
in a dissimilar overall structure for CETP (Bruce et al., 1998a; Qiu et al., 2007). 
 
 
 
 
 
 
 
 
 
Figure 3. Overall structure of CETP (Qiu et al., 2007). a) The N-terminal domain is 
shown in green and the C-terminal domain in yellow, with the linker in red. CE1 
(magenta) and CE2 (cyan) are shown as space fills and PLs as black bonds. N-
glycosylation sites at residues 341 and 396 are labeled. ‘5’ represents the N-terminus 
of the molecule. Helices A, B, A’, B’ and X are labeled. Helix X belongs to the C-
terminal domain but interacts with the N-terminal domain. b) The structure after a 90º 
rotation. The four structural units are shown; the N-terminal barrel in green, the 
central β-sheet in orange, the C-terminal barrel in yellow, and the helix X in cyan. N-
glycosylation sites at residues 88 and 240 are labeled.  
The earlier hypothesis was that the CETP molecule contains one neutral lipid-
binding site and one PL-binding site (Bruce et al., 1998a). This was based on 
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quantitative analyses, which had indicated that 1.0 mol of CETP is able to bind 1.0 
mol of cholesterol, 0.5 mol of TGs, and 1.3 mol of PLs (Connolly et al., 1996). 
However, the detailed crystal structure of CETP demonstrates that CETP can bind 
two neutral lipids and two PLs (Qiu et al., 2007). The binding sites for neutral lipids 
can accommodate two CEs, one CE and one TG, or possibly two TGs. The CETP 
molecule contains a 60-Å-long continuous tunnel with a large volume (2560 Å3).The 
tunnel traverses the core of the molecule and has two distinct openings, the N- and 
C-terminal openings. The cross-sectional areas of both openings and the dimensions 
of the tunnel are large enough to allow lipid access and passage of neutral lipids. 
The observation that CE transfer is faster than TG transfer may be due to the fact 
that smaller CE molecules can pass through the tunnel with less resistance than 
larger TG molecules (Ohnishi et al., 1995; Connolly et al., 1996). The C-terminal 
end of the CETP molecule, including the helix X, is essential for proper functioning 
of CETP, as deletion mutants lacking amino acids 470-475 showed defective 
binding of CEs and TGs, suggesting the importance of helix X in the transfer of 
neutral lipids (Wang et al., 1995). However, deletion of the C-terminus had no effect 
on the binding of PLs by CETP or the association of CETP with HDL. Amino acids 
Lys233 and Arg259, highly conserved residues within the LT/LBP family, are 
necessary for the CE transfer activity of CETP, possibly by mediating the binding of 
CETP to lipoproteins (Jiang et al., 1995). 
The concave surface of the CETP molecule is the most probable site for 
lipoprotein binding, as it contains the N-terminal and C-terminal openings of the 
tunnel, helix X and the 1 flap (Qiu et al., 2007). The binding of lipoproteins to the 
other surfaces of CETP is unlikely, since they lack proper curvatures to bind 
spherical lipoproteins and direct access to the tunnel, and they are highly 
glycosylated. CETP has a higher binding affinity towards 10-nm-diameter nascent 
discoidal HDL particles than towards particles with a smaller diameter (Bruce et al., 
1995), and this corresponds to the diameter of the concave surface of CETP. Thus, 
the authors hypothesized that CETP can bind a single HDL particle on the concave 
face of the CETP molecule (Qiu et al., 2007). The binding of HDL may cause slight 
movements of helix X and the 1 flap, and helix X may also be partially inserted 
into the bound lipoprotein. The overall HDL particle size and shape as well as lipid 
composition have a significant effect on the binding of CETP to HDL (Bruce et al., 
1995). Moreover, these results indicated that binding of CETP to cholesterol- and 
CE-containing discs was increased, which suggests that CETP has a higher affinity 
for nascent HDL than for mature HDL.  
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2.4.2 Functions of CETP  
Lipid transfer 
CETP enhances the redistribution of CEs, TGs, and to lesser extent, PLs between 
plasma lipoproteins (Tall, 1993; Barter et al., 2003b). CETP mediates the 
heteroexchange of CEs in HDL for TGs in triglyceride-rich lipoproteins (TRL). 
Thus, the overall effect of CETP is a net mass transfer of CEs from HDLs into TRLs 
and LDL particles and of TGs from TRLs to HDL and LDL particles. The functions 
of CETP and PLTP in vivo are nonoverlapping (Kawano et al., 2000). Both CETP 
and PLTP are able to mediate the transfer of PLs from PC-containing HDL particles 
to LDL, but unlike PLTP, CETP is unable to transfer PLs from PC-containing 
liposomes to HDL (Lagrost et al., 1994). CETP was shown to induce redistribution 
of HDL3 particles containing both apoA-I and apoA-II towards two particle 
subpopulations, one with a larger and the other with a smaller diameter compared 
with original particles (Lagrost, 1992).  
Based on the crystal structure of CETP, a mechanism for CETP-mediated 
lipid transfer was suggested (Figure 4) (Qiu et al., 2007). The concave surface of 
the CETP molecule and the curvature of a 10-nm HDL particle are well suited to 
each other. Nevertheless, when CETP binds larger VLDL particles (30-100 nm), it 
must adopt a straighter conformation. It is unlikely that CETP can affect the surface 
curvature of VLDL particles. Instead, CETP can adopt a more gently curved 
conformation by twisting its barrels around the central β-sheet without significantly 
affecting the shape of the tunnel. Structural units of CETP may facilitate binding of 
lipoprotein to CETP, as access to the N-terminal opening is aided by helix X being 
inserting into the PL monolayer and facilitating neutral lipid exchange, whereas the 
1 flap may help lipids access to the C-terminal opening. The neutral lipid transfer 
between lipoproteins in plasma occurs mainly by heteroexchange, as TG transfer 
activity was shown to be essential for CE transfer (Ko et al., 1994).  
As long as it remains at a moderate level, plasma VLDL concentration is the 
driving force for the transfer of CEs (Mann et al., 1991). In hypertriglyceridemia, 
VLDL concentration increases and CETP becomes a rate-limiting factor that inhibits 
the net transfer of CEs from HDL. At normal VLDL levels, CEs are directed from 
HDL particles mainly to LDL, whereas at higher VLDL levels, large VLDL1 
particles are the preferential acceptors of CEs from HDL (Guerin et al., 2001). The 
total transfer of CE mass from HDL to total TRLs, including CMs, VLDL1, VLDL2 
and IDL, was shown to be increased in the postprandial state, thus causing 
accumulation of CE-rich remnant particles of elevated atherogenicity (Guerin et al., 
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2002). However, despite increased CETP activity, no changes in PLTP activity were 
observed in the postprandial state, indicating that plasma CETP and PLTP activities 
are differentially regulated (Syeda et al., 2003).  
 
 
 
 
 
 
 
Figure 4. Proposed mechanism for CETP-mediated lipid transfer (Qiu et al., 2007). 
TG-rich VLDL is shown in blue and CE-rich HDL in green. Step 1, CETP filled with 
CE binds VLDL and releases the bound phospholipids (PC).  Then, one or two TGs 
can enter the tunnel and an equal amount of CE is transferred into VLDL. Step 2, the 
TG-bound CETP dissociates from VLDL and leaves the VLDL particle with a higher 
CE content. Step 3, the TG-bound CETP binds HDL and releases the PCs. Next, one 
or two new CEs enter the tunnel and an equal amount of TG is transferred into HDL. 
Step 4, the CE-filled CETP dissociates from HDL and completes a full cycle of 
heteroexchange. The openings of the tunnel are refilled with PCs before dissociation 
of CETP from the lipoproteins to allow the return to the aqueous environment. 
Elevated plasma CETP levels accompanied by increased peripheral CE transfer to 
TRLs and LDL have been observed in patients with various atherogenic 
dyslipidemias (McPherson et al., 1991). CETP was shown to contribute to an 
atherogenic lipid phenotype in several ways. By increasing the CE content of VLDL 
particles, it increases the atherogenicity of VLDLs (Chung et al., 1998). Moreover, 
CETP increases the formation of small, dense LDL particles (Chung et al., 1998; 
Guerin et al., 2001) as well as very small HDL particles (Newnham and Barter, 
1990). CETP-mediated lipid transfer was shown to cause a reduction in HDL 
particle size (Liang et al., 1994; Rye et al., 1995; Rye et al., 1997), which was 
associated with a dissociation of lipid-poor preβ-migrating apoA-I from HDL (Liang 
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et al., 1994; Rye et al., 1995). However, the capability of CETP to generate preβ-
HDL is essentially lower than that of PLTP (Lie et al., 2001). Characterization of 
plasma CETP activity in the early phase of acute myocardial infarction revealed that 
high CE transfer rates are related to the presence of high non-HDL cholesterol, high 
CETP mass, and low HDL2b concentration in young patients, suggesting the 
contribution of CETP to the accelerated progression of the disease among subjects 
without clinical symptoms (Zeller et al., 2007). In addition, plasma CETP levels 
might be related to risks of thrombotic events, as coagulation via both intrinsic and 
extrinsic pathways were positively correlated with plasma levels of CETP, 
increasing the activation of prothrombin (Deguchi et al., 2007).  
Reverse cholesterol transport 
As early as the 1980s it was suggested that CETP may promote cholesterol removal 
from cells of the human aortic wall (Stein et al., 1986). Later on, the presence of 
CETP in the foam cells of human aortic and coronary atherosclerotic lesions, but not 
in normal arteries, was demonstrated, suggesting that CETP might have a function in 
the removal of cholesterol from cells in the arterial wall (Zhang et al., 2001b). HDL-
mediated efflux of FC from the COS-7 cells that express CETP was significantly 
increased, while the uptake of HDL lipids was unaltered compared with control 
mock-transfected cells. Furthermore, decreased cholesterol efflux was observed 
from macrophages obtained from CETP-deficient subjects compared with 
macrophages obtained from subjects with normal CETP expression. The ability of 
HDL derived from CETP-deficient subjects to promote removal of cholesterol from 
LXR-activated macrophages was studied recently (Matsuura et al., 2006). HDL2 
from CETP-deficient subjects showed 2-3-fold stimulation in ABCG1-mediated net 
cholesterol efflux compared with control HDL2. The enhanced ability of HDL2 to 
promote cholesterol efflux was associated with increased LCAT and apoE contents 
of HDL2 particles. Besides ABCG1, efflux pathways mediated by SR-BI and 
ABCA1 were shown to be functional when sera from CETP-deficient subjects were 
used as cholesterol acceptors (Miwa et al., 2009). Moreover, increased plasma 
CETP activity and increased cholesterol efflux from Fu5AH cells to plasma samples 
were observed during the postprandial state in normolipidemic men (Syeda et al., 
2003). However, no correlation of plasma CETP activity with plasma cholesterol 
efflux capacity was observed in this study. Recently, a decrease in plasma CETP 
activity accompanied by decreased cholesterol efflux from THP-1 macrophages to 
plasma samples obtained from subjects treated with rosuvastatin was observed 
(Sviridov et al., 2008). 
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2.4.3 CETP deficiency as a predictor of atherosclerosis 
CETP deficiency reportedly exists in humans (Brown et al., 1989; Inazu et al., 
1990). It is associated with a potentially antiatherogenic lipoprotein profile, as 
subjects homozygous for CETP deficiency exhibited substantially elevated HDL and 
apoA-I levels and decreased LDL and apoB levels (Inazu et al., 1990). Subjects 
heterozygous for CETP deficiency had lowered plasma CETP levels accompanied 
by moderately increased levels of HDL and apoA-I and an increased HDL2/HDL3 
ratio. CETP deficiency was shown to result in the formation of large HDL particles 
containing all the major apolipoproteins, apoA-I, apoA-II, apoC (I, II, III), and 
apoE, except for apoA-IV (Asztalos et al., 2004). Subjects heterozygous for CETP 
deficiency had increases in large α-1 and preα-1 particles, whereas preβ1-HDL was 
lower. The increased HDL levels in CETP-deficient subjects have been shown to be 
due to delayed catabolism of apoA-I and apoA-II without changes in the production 
rates of apolipoproteins (Ikewaki et al., 1993). The HDL fraction from subjects 
deficient in CETP was especially enriched in large apoE- and CE-rich HDL particles 
(Yamashita et al., 1990). When the effect of HDL isolated from patients 
homozygous for CETP deficiency on the accumulation and removal of cholesterol 
was studied, the large apoE-free, CE-rich HDL2 particles from CETP-deficient 
subjects had decreased ability to prevent cholesterol accumulation into macrophages 
and remove cholesterol from lipid-laden macrophages while HDL3 particles were 
functional (Ishigami et al., 1994). 
 
2.4.4 Animal models of atherosclerosis with modified CETP expression 
Mice, among several other species, are naturally deficient in CETP, and therefore 
introduction of the human CETP transgene into mice has provided an opportunity to 
study the effect of CETP on lipoprotein metabolism and RCT. Expression of the 
CETP transgene in mice caused a significant decrease in plasma HDL level (Agellon 
et al., 1991; Jiang et al., 1993) as well as increased VLDL and LDL cholesterol and 
apoB levels (Jiang et al., 1993). With increasing CETP concentration, hepatic LDLr 
mRNA abundance was progressively decreased, leading to accumulation of apoB-
containing lipoprotein particles. Introduction of the simian CETP transgene into 
mice was shown to result in more severe atherosclerosis compared with 
nontransgenic controls, probably due to CETP-induced changes in lipoprotein 
distribution (Marotti et al., 1993). The effect of bone marrow-derived CETP on 
atherosclerosis was studied by transplanting bone marrow from huCETPtg mice into 
LDL-/- mice (Van Eck et al., 2007). Bone marrow-derived CETP increased plasma 
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VLDL and LDL cholesterol and decreased HDL cholesterol, and these changes in 
CE distribution were accompanied with enhanced formation of atherosclerotic 
lesions. However, macrophage CETP production showed no effect on cholesterol 
efflux. Furthermore, the results of this study demonstrated that bone marrow-derived 
cells, including macrophages, are important contributors to total serum CETP 
activity and mass.  
The effect of CETP on the RCT process is unclear, as both promotion and 
inhibition of RCT have been reported in animal studies. Targeted expression of 
CETP in the livers of different mouse models demonstrated that CETP expression 
promoted macrophage RCT despite a reduction in plasma HDL cholesterol levels, 
and this effect of CETP required the presence of LDLr (Tanigawa et al., 2007). 
Previous results have shown that CETP-mediated remodeling of HDL leads to 
enrichment of HDL with TGs, and subsequent lipolysis of TG-rich HDL by HL can 
promote the uptake of CEs from HDL by hepatic SR-BI (Collet et al., 1999). 
Moreover, later results have indicated that CETP is able to restore to normal the rate 
of RCT in mice deficient in SR-BI (Tanigawa et al., 2007). This observation is in 
agreement with the results demonstrating that CETP is able to mediate selective 
uptake of CEs from HDL by hepatocytes via a mechanism independent of SR-BI 
and LDL receptors (Gauthier et al., 2005), suggesting that CETP is involved in a 
physiological system that facilitates functional RCT. Moreover, recent results 
demonstrated that both CETP overexpression and inhibition of CETP activity by 
torcetrapib may result in enhancement of the RCT process (Tchoua et al., 2008). In 
contrast, no enhancement of RCT was observed when simian (Stein et al., 2002) or 
human CETP (Rotllan et al., 2008) was expressed in mice. CETP overexpression 
was also unable to improve the protection conferred by HDL against oxidative 
modification of LDL, and the result was consistent with the absence of effects of 
CETP expression on plasma activities of antioxidative HDL enzymes PON-1 and 
PAF-AH (Rotllan et al., 2008).  
In certain circumstances, CETP expression may have antiatherogenic rather 
than proatherogenic effects in mice. In hypertriglyceridemic human apoC-III 
transgenic mice, decreased development of atherosclerotic lesions due to CETP 
expression was observed (Hayek et al., 1995). Also another study demonstrated that 
the human CETP transgene was antiatherogenic in hypertriglyceridemic mice 
produced by streptozotocin-induced diabetes and LPL deficiency (Kako et al., 
2002). In a diabetic mouse model, db/db mice, CETP expression led to lower plasma 
total cholesterol, VLDL and LDL cholesterol, and attenuated the development of 
atherosclerotic lesions, which suggests that in the context of diabetic obesity, CETP 
might be antiatherogenic (MacLean et al., 2003). In ovariectomized mice, CETP 
expression was accompanied by lower plasma levels of total cholesterol, VLDL, 
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LDL, and HDL cholesterol, as well as lower titers of antibodies against oxidized 
LDL and smaller mean aortic lesion areas (Cazita et al., 2003). These results 
suggested that CETP expression can compensate for the lack of estrogen. 
 
2.4.5 Therapeutic interventions affecting CETP activity 
Animal studies 
As rabbits have a naturally high plasma level of CETP and extremely high 
susceptibility to atherosclerosis, rabbits have been widely used to study the effects 
of CETP inhibition on the development of atherosclerosis. Several compounds have 
been generated for inhibition of CETP activity. One of these is JTT-705, which is a 
synthetic compound that inhibits CETP activity by forming a disulphide bond with 
CETP. When CETP activity was inhibited in mildly hypercholesterolaemic rabbits 
by administering JTT-705 for six months, a 90% elevation in plasma HDL 
cholesterol, a 40-50% reduction in non-HDL cholesterol and a 70% decrease in 
lesion area were observed (Okamoto et al., 2000). JTT-705 increased both HDL2 and 
HDL3, while the increase of HDL2 was more pronounced. However, in rabbits with 
more severe hypercholesterolaemia, JTT-705 was unable to inhibit the extent of 
atherosclerotic lesions, despite a significant increase in plasma HDL (Huang et al., 
2002). In a second study, non-HDL cholesterol decreased less compared with the 
first study (25% vs. 40-50%), and the results demonstrated that the extent of the 
lesion area correlated with non-HDL cholesterol but not with HDL cholesterol. The 
increase in HDL levels in JTT-705-treated Japanese White rabbits was shown to be 
due to increased apoA-I synthesis without changes in the rate of fractional 
catabolism of apoA-I (Shimoji et al., 2004). In addition to increased HDL levels and 
an increased HDL2/HDL3 ratio, JTT-705 treatment of rabbits increased the apoE 
content of HDL as well as the PL content of apoE-rich HDL (Zhang et al., 2004). 
The activities of HDL-associated enzymes, PON-1 and PAF-AH, were increased, 
indicating that CETP inhibition by JTT-705 has several beneficial effects on plasma 
HDL. 
Torcetrapib is a potent inhibitor of CETP activity, which by enhancing the 
association between CETP and HDL leads to the formation of complexes that inhibit 
lipid transfer between HDL and other lipoproteins (Barter and Kastelein, 2006). 
Administration of torcetrapib to hamsters elevated plasma HDL levels and enhanced 
RCT in vivo (Tchoua et al., 2008). In hyperlipidemic ApoE*3-Leiden.CETP 
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transgenic (E3L.CETP) mice, torcetrapib increased plasma HDL levels by 30% and 
reduced atherosclerotic lesion size by 43% (de Haan et al., 2008a). However, 
atorvastatin caused a similar reduction in lesion size, and a combination of 
torcetrapib and atorvastatin failed to cause a further decrease in lesion size compared 
with atorvastatin alone. Furthermore, torcetrapib changed the phenotype of lesions 
towards a more unstable and proinflammatory state characterized by an increased 
macrophage and a decreased collagen content. Also statins are able to inhibit CETP 
activity, as increased plasma HDL levels in E3L.CETP mice were accompanied by 
decreased circulating CETP activity caused by down-regulation of hepatic CETP 
mRNA expression by atorvastatin (de Haan et al., 2008b). Besides beneficial effects 
of torcetrapib on HDL levels, elevated blood pressure associated with increased 
circulating levels of aldosterone and corticosterone were found in several animal 
species, including mice, rats, dogs, and rhesus monkeys, following torcetrapib 
treatment (Forrest et al., 2008). However, the observed changes are probably 
independent of CETP inhibition, as no increase in blood pressure or adrenal steroids 
was observed with another CETP inhibitor, anacetrapib. 
Vaccines against CETP are one approach to inhibiting plasma CETP activity 
that is under investigation. Intramuscular immunization of rabbits with a chimeric 
peptide containing a region of CETP necessary for neutral lipid transfer decreased 
plasma CETP activity significantly and resulted in 42% higher HDL, 24% lower 
LDL, and ~40% smaller aortic lesion area compared with control-vaccinated rabbits 
(Rittershaus et al., 2000). A search for non-invasive routes for immunization against 
atherosclerosis has led to development of intranasal vaccinations (Yuan et al., 2008). 
Intranasal and intramuscular immunizations using a DNA vaccine against CETP 
resulted in a similar reduction in aortic lesion area (~60% and ~70%, respectively) 
in rabbits, suggesting that non-invasive intranasal vaccination might be used for 
therapeutic purposes.  
 Human studies 
After studies conducted in animals, the function and effectiveness of CETP 
inhibitors have been tested in carefully controlled trials in humans. When CETP 
inhibitor JTT-705 was tested in a phase II, randomized, double-blind, placebo-
controlled study of healthy subjects with mild dyslipidemia, a dose-dependent 
decrease in CETP activity and an increase in HDL cholesterol were observed, 
accompanied by a minimal decrease in LDL cholesterol (de Grooth et al., 2002). A 
combination of pravastatin and JTT-705 was assessed in a randomized, double-
blind, placebo-controlled trial in subjects with type II dyslipidemia using pravastatin 
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(Kuivenhoven et al., 2005). Four weeks of treatment with JTT-705 led to a 30% 
decrease in CETP activity and a 28% increase in HDL cholesterol, while LDL 
cholesterol decreased by ~5%. In both trials, JTT-705 was shown to be safe and well 
tolerated.  
Torcetrapib was tested in 40 healthy individuals randomized to receive either 
a placebo or torcetrapib in doses increasing from 10 to 240 mg daily for 14 days 
(Clark et al., 2004). The mean inhibition of CETP activity was from 12% to 80%, 
depending on the dose of torcetrapib. HDL cholesterol concentration increased by 
16% to 91%, whereas that of LDL decreased by 21% to 42%. These changes were 
accompanied with increased apoA-I and apoE and decreased apoB concentrations. 
Torcetrapib reduced VLDL, IDL, and LDL apoB-100 levels by increasing the rate of 
apoB-100 clearance (Millar et al., 2006), and VLDL apoE levels by increasing 
VLDL apoE clearance (Millar et al., 2008). In another study conducted in 19 
subjects with low HDL levels, torcetrapib at a daily dose of 120 mg increased 
plasma HDL concentration by 61% or 46% in the presence or absence of 
concomitant therapy with atorvastatin, whereas treatment with torcetrapib alone at a 
dose of 120 mg twice daily increased HDL cholesterol by 106% (Brousseau et al., 
2004). The mean size of HDL particles increased following treatment with 
torcetrapib, which is in good agreement with the previous results of large HDL 
particles observed in individuals with a genetic deficiency in CETP (Matsuura et al., 
2006). Torcetrapib increased plasma apoA-I in HDL by delaying apoA-I catabolism 
(Brousseau et al., 2005). Recently, enhanced cholesterol efflux from macrophage 
foam cells due to increased HDL levels and improved particle functionality was 
observed following torcetrapib administration in humans (Yvan-Charvet et al., 
2007a). Torcetrapib may modulate the biological activities of HDL2 and HDL3 
particles and thus affect their function in RCT (Catalano et al., 2009). However, in 
another study, no increase in overall RCT in humans, measured by fecal sterol, was 
found by torcetrapib, regardless of increased HDL levels (Brousseau et al., 2005).  
Torcetrapib has already been tested in humans in large, long-term trials 
(Barter et al., 2007b; Bots et al., 2007; Kastelein et al., 2007; Nissen et al., 2007). At 
the end of 2006, all torcetrapib clinical trials were terminated in the interest of 
patient safety. Torcetrapib increased HDL cholesterol and decreased LDL 
cholesterol in each study, although significantly more major cardiovascular events 
were observed in the group receiving torcetrapib in combination with atorvastatin 
than in the group receiving atorvastatin monotherapy (Barter et al., 2007b). 
Furthermore, torcetrapib failed to attenuate the progression of atherosclerosis in the 
common carotic arteries (Bots et al., 2007; Kastelein et al., 2007) and coronary 
arteries (Nissen et al., 2007), and it increased systolic blood pressure in all the trials. 
Whether the lack of efficacy and the observed adverse effects are related to the 
 57 
 
mechanism of drug class, i.e. CETP inhibition, or to molecule-specific properties, 
needs to be determined. In two double-blind, randomized, placebo-controlled phase 
I studies in healthy individuals and in patients with dyslipidemia, anacetrapib, a 
CETP inhibitor of the same structural class as torcetrapib, increased HDL 
cholesterol and decreased LDL cholesterol without any effects on blood pressure, 
suggesting that CETP inhibition itself might not lead to increased blood pressure 
(Krishna et al., 2007). It has been postulated that torcetrapib can lead to the 
formation of HDL particles that function improperly or are proinflammatory (Singh 
et al., 2007). 
CETP vaccine has also been tested in humans. However, in a phase I trial 
only one patient out of a total of 36 patients at the highest dose of a single injection 
of CETP vaccine developed auto-antibodies against CETP (Davidson et al., 2003). 
Following a second injection of vaccine, 8 patients out of a total of 23 patients had a 
measurable antibody response, whereas no response was observed in a placebo 
group.  
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3 AIMS OF THE STUDY 
I) To study the role of endogenous PLTP in the removal of cholesterol from 
macrophage foam cells.  
II) To determine the effects of macrophage-derived PLTP on the development of 
atherosclerosis. 
III) To clarify the role of HA-PLTP and LA-PLTP in the removal of cholesterol from 
macrophage foam cells. 
IV) To determine the effect of CETP on cholesterol efflux from macrophage foam cells 
and whether chymase affects degradation of CETP and its function in the efflux process.  
 
V) To investigate whether monocyte macrophages derived from low- and high-HDL 
subjects differ in cholesterol efflux and whether their sera differ as cholesterol 
acceptors. 
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4 MATERIALS AND METHODS 
4.1 LIST OF PUBLISHED METHODS 
The methods used in this thesis project are listed in the table below in alphabetical 
order. The original publications in which the methods appear are indicated by the 
Roman numerals. 
Method Original publication 
Acetylation of LDL I, III, IV, V
Bone marrow isolation and transplantation II 
Cell culture I, II, III, IV, V 
CETP activity assay IV, V 
Cholesterol efflux assays I, III, IV, V 
Crossed immunoelectrophoresis   I, II, III, IV, V 
Enhanced chemiluminescence detection  IV, V 
Enzymatic lipid analysis                                            II, III, V  
Hepatic cell separation II 
Hepatic lipase activity assay  II 
Histological analysis of the aortic root II 
Immunohistochemistry II 
Immunoprecipitation of preβ-HDL III 
Isolation of leukocytes from buffy coat III, V 
Isolation of peritoneal leukocytes I 
LCAT activity assay                                                   II, V  
Lipid extraction I, III, V 
Lowry protein determination  I, III, IV, V 
Non-denaturing gradient gel electrophoresis III, V 
Plasma apolipoprotein and lipoprotein analysis I, II, III, IV, V 
Plasma CRP and glucose analysis V 
PLTP activity assay I, II, III, IV, V 
PLTP ELISA  II, III, V 
Purification of CETP IV 
Purification of PLTP   III, IV 
Radiolabeling of acetylated LDL I, III, IV, V 
Real-time quantitative PCR II, V 
SDS-PAGE and Western blotting IV, V 
Size-exclusion chromatography II, III 
Statistical analysis I, II, III, IV, V 
Thin layer chromatography I, III, V 
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5 RESULTS AND DISCUSSION 
5.1 Absence of endogenous PLTP impairs ABCA1-dependent 
efflux of cholesterol from macrophage foam cells (I) 
Data on the participation of exogenously added PLTP in cholesterol efflux from 
cells are available (von Eckardstein et al., 1996; Wolfbauer et al., 1999; van Haperen 
et al., 2000; Lee et al., 2003; Oram et al., 2003), whereas the role of endogenous 
PLTP in the efflux process is unclear. As foam cells present in human 
atherosclerotic plaques contain an abundant amount of PLTP (Desrumaux et al., 
2003; Laffitte et al., 2003; O'Brien et al., 2003), it raises the possibility that 
endogenous PLTP may also participate in RCT. To address this question, ABCA1-
dependent efflux of cholesterol from peritoneal macrophages derived from PLTP-
KO mice was compared with that from macrophages derived from wild-type (WT) 
mice.  
5.1.1 Cholesterol efflux to HDL3, apoA-I, and plasma 
First, the morphological features of PLTP-KO and WT macrophages loaded in the 
presence of [3H]CE-acetyl-LDL were compared. The morphological features of 
cholesterol-loaded PLTP-KO and WT macrophages were similar when evaluated by 
light microscopy (I, Fig. 1). The viabilities of the PLTP-KO and WT macrophages 
with or without acetyl-LDL loading did not differ.  
Next, the efflux of cholesterol from PLTP-KO and WT macrophages, both in 
their basal state and after their conversion to foam cells, to HDL3 was investigated. 
For the efflux studies, peritoneal macrophages were labeled by exposing the cells to 
[3H]free cholesterol for 24 h in the presence of an ACAT inhibitor, Sandoz 58-035 
compound (Ross et al., 1984), or cholesterol-loaded by incubating them with 
[3H]CE-acetyl-LDL for 18 h. Cholesterol efflux from the nonloaded macrophages 
was low, and no significant effect of PLTP was evident. However, when the 
macrophages were loaded with acetyl-LDL, high-affinity and saturable efflux of 
cholesterol to HDL3 was observed (Figure 5A). Cholesterol efflux from PLTP-KO 
macrophages loaded with acetyl-LDL was significantly reduced (P < 0.05) 
compared with cholesterol-loaded WT macrophages. The Km value was 2-fold 
higher for PLTP-KO macrophages than for WT macrophages (15.6 vs. 8.2 μg/ml, 
respectively). These results suggest that PLTP deficiency disturbed ABCA1-
mediated cholesterol efflux involving cholesterol mobilization from late endocytic 
compartments (Chen et al., 2001), rather than efflux of FC from cell surfaces. 
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To characterize the role of PLTP in cholesterol efflux, cholesterol efflux from 
cholesterol-loaded macrophages to human lipid-free apoA-I was studied. The 
expression of ABCA1 is very low in nonloaded macrophages, while cholesterol 
loading leads to the formation of macrophage foam cells with subsequent 
overexpression of ABCA1 (Langmann et al., 1999). The rate of cholesterol efflux to 
apoA-I was higher from WT than from PLTP-KO macrophage foam cells at all 
apoA-I concentrations tested (Figure 5B). As ABCA1 mediates cholesterol efflux to 
apoA-I, the results demonstrate that the absence of endogenous PLTP impairs 
ABCA1-mediated cholesterol efflux. 
In addition to HDL and apoA-I, plasma was used as a cholesterol acceptor. 
Plasma has been widely used as a cholesterol acceptor in efflux studies, as it 
represents a more physiological acceptor (Fielding and Fielding, 1995). When 
cholesterol efflux from WT macrophages was studied, plasma from WT mice 
promoted higher cholesterol efflux than plasma from PLTP-KO mice (I, Fig. 4). 
Moreover, WT plasma promoted less efficient cholesterol efflux from PLTP-KO 
macrophages than from WT macrophages. Normalization of efflux values for the 
plasma apoA-I concentration did not change the results markedly, which confirms 
that endogenous PLTP has an essential role in the cholesterol efflux process from 
macrophages. 
 
Figure 5. Cholesterol efflux from PLTP-KO and WT macrophages to HDL3 (A) and 
apoA-I (B). Each value is the mean of triplicate wells ± SD. * P < 0.05. Km values are 
shown in the insets. 
5.1.2 Cholesterol loading of macrophages 
Following the observed differences in cholesterol efflux, the ability of PLTP-KO 
and WT macrophages to take up acetyl-LDL was compared. Loading of 
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macrophages with acetyl-LDL increased their cellular lipid content and stimulated 
formation of foam cells in both PLTP-KO and WT macrophages (I, Table 1). 
However, the intracellular FC and CE contents of PLTP-KO and WT macrophages 
loaded with various concentrations of acetyl-LDL did not differ, verifying that 
genetic deficiency in PLTP does not prevent foam cell formation and thereby affect 
the efflux process. 
5.1.3 Cholesterol efflux under the stimulation of ABCA1  
Stimulation with cAMP leads to upregulation of the expression and activity of 
ABCA1 in murine macrophages (Oram et al., 2000; Kiss et al., 2005). It was 
therefore of interest to study the effect of 8-(4-chlorophenylthio)adenosine 3',5'-
cyclic monophosphate (cAMP) on cholesterol efflux from nonloaded and 
cholesterol-loaded PLTP-KO and WT macrophages to apoA-I. Treatment of mouse 
macrophages with cAMP increases the expression of ABCA1 without any effects on 
the expression of ABCG1 (Khovidhunkit et al., 2003). In contrast to nonloaded cells, 
the co-stimulatory effect of cholesterol loading and cAMP treatment on ABCA1-
mediated cholesterol efflux caused a clear enhancement of cholesterol efflux from 
PLTP-KO macrophages and resulted in similar levels of cholesterol efflux from 
PLTP-KO and WT macrophages (I, Fig. 5). These results suggest that PLTP 
deficiency can be compensated by stimulation of ABCA1 expression and ABCA1-
mediated cholesterol efflux. In a previous report (Cao et al., 2002), only minimal 
reduction was found in the efflux capacity of PLTP-KO macrophage foam cells 
compared with WT macrophage foam cells before or after LXR stimulation. A 
possible explanation for this observed difference between the results may be due to 
responses induced by an inflammatory challenge (Cook et al., 2003) brought about 
by thioglycollate exposure of the elicited macrophages in the previous study, 
whereas in this study the macrophages were collected without thioglycollate 
treatment. 
 
5.2 Macrophage PLTP contributes significantly to total plasma 
phospholipid transfer activity and its deficiency leads to 
diminished atherosclerotic lesion development (II) 
To evaluate the role of macrophage PLTP in lipoprotein metabolism and in the 
development of atherosclerotic lesions, PLTP gene expression was specifically 
disrupted in cells of hematopoietic origin by bone marrow transplantation. 
Development of atherosclerotic lesions was induced by feeding the mice with a 
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Western-type diet (WTD) containing 15% (w/w) total fat and 0.25% (w/w) 
cholesterol for 9 weeks.  
5.2.1 Effect of macrophage PLTP deficiency on atherosclerosis 
Lesion development was analyzed in the aortic root of the PLTP+M/+M and  
PLTP–M/–M mice after 9 weeks of WTD feeding. Macrophage PLTP deficiency led to 
a 29% (P < 0.01) decrease in mean atherosclerotic lesion area (Figure 6). 
Macrophage PLTP deficiency showed no significant effect on the relative 
macrophage content of the lesions. Instead, macrophage PLTP deficiency led to 
slightly reduced collagen content (P = 0.07) and significantly smaller cap thickness 
(P < 0.01) in the lesions compared with PLTP+M/+M mice, which could be related to 
the smaller lesion size observed in PLTP–M/–M animals.  
5.2.2 Measurement of serum lipid levels and lipoprotein distribution 
The decreased lesion size in the PLTP-M/-M group coincided with significantly lower 
serum total cholesterol (TC), FC (P < 0.05 for both TC and FC), and TG (P < 0.01) 
levels in these mice compared with PLTP+M/+M mice. All the other details are shown 
in Table 1 (II). Macrophage PLTP deficiency showed no significant effect on 
circulating preβ-HDL levels at 8 weeks posttransplantation, whereas 24% lower 
preβ-HDL levels were observed in PLTP–M/–M mice compared with PLTP+M/+M mice 
after 9 weeks of WTD feeding (P < 0.05). Lesion development was reduced in 
PLTP-M/-M mice in spite of the decreased levels of preβ-HDL, which implicates that 
the proatherogenic effects of lower preβ-HDL levels were overruled by other factors. 
Higher plasma apoA-I levels and HDL PLs observed in PLTP-M/-M mice may lead to 
formation of HDL subclasses with a higher acceptor potential in the efflux process, 
leading to decreased lesion size. 
PLTP activity (Damen et al., 1982; Jauhiainen et al., 1993) was almost 
exclusively associated with HDL lipoproteins in both groups. Plasma PLTP activity 
was 1.4-fold lower in the PLTP–M/–M group compared with the PLTP+M/+M group on 
chow diet (P < 0.01) and 2-fold lower during WTD (P < 0.001). These data 
demonstrate that macrophage PLTP is an important contributor to plasma PLTP 
activity.  
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Figure 6.  Atherosclerotic lesion formation in LDLr–/– mice with macrophage PLTP 
deficiency. Values represent the means ± SEM calculated from 14 PLTP+M/+M mice 
and 10 PLTP–M/–M mice. **P < 0.01. Original magnification x50.  
5.2.3 PLTP activity and expression in the liver and lung 
PLTP is a ubiquitously expressed protein with a moderate level of expression in the 
liver (Albers et al., 1995). Despite only moderate hepatic PLTP expression, the liver 
as a large organ can significantly contribute to circulating PLTP levels. PLTP 
mRNA expression in whole liver tissue samples taken from PLTP+M/+M and  
PLTP–M/–M mice at 17 weeks posttransplantation was studied. PLTP expression was 
slightly reduced in livers from the PLTP–M/–M mice compared with livers from the 
PLTP+M/+M animals. In accordance with the mRNA data, PLTP activity levels in the 
liver homogenates were 26% lower in the PLTP–M/–M mice (P = 0.0019) (II, Fig. 3). 
These results confirm the importance of bone marrow cells in hepatic PLTP 
production.  
The liver contains several different types of cells, of which the majority are 
parenchymal cells, which contribute 92.5% of the total mass of liver protein. Other 
cell types, endothelial cells and Kupffer cells, account for 3.3% and 2.5% of the 
mass of liver protein, respectively (Blouin et al., 1977; Nagelkerke et al., 1983). Of 
the hepatic cells, Kupffer cells are resident macrophages of the liver and of 
hematopoietic origin. In the present study, expression of PLTP mRNA was 6-fold  
(P < 0.01) higher in Kupffer cells compared with parenchymal cells, whereas 
endothelial cells produced only a minority of PLTP mRNA. As a consequence, 
Kupffer cells contribute approximately 14% of the total expression of liver PLTP, 
despite the low contribution to total liver protein. Parenchymal cells and endothelial 
cells contributed 85.7% and 0.5% of the total liver PLTP mRNA, respectively. As 
plasma PLTP activity reportedly correlates positively with TG levels (Janis et al., 
2004), and macrophage PLTP deficiency resulted in substantially lower plasma 
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VLDL levels, it is conceivable that PLTP from Kupffer cells could also directly or 
indirectly influence VLDL biosynthesis or secretion.  
In addition to liver, PLTP is expressed in the lungs, where the expression 
level is very high (Albers et al., 1995). Localizations of PLTP and macrophages 
were analyzed in liver and lung samples from PLTP+M/+M and PLTP–M/–M mice. 
Immunohistochemical localization of PLTP protein in the livers and lungs of 
PLTP+M/+M and PLTP–M/–M mice clearly demonstrated a reduction in PLTP protein 
expression due to disruption of PLTP in bone marrow-derived cells (II, Fig. 4). 
Moreover, macrophage PLTP deficiency resulted in a clear decrease in PLTP 
expression in the bronchioles of the lung. The results demonstrate that the significant 
contribution of Kupffer cells to PLTP expression and production, combined with 
that of other resident macrophages in the lung, adipose tissue, and spleen, may 
explain the observed effects of PLTP deficiency in hematopoietic cells on 
lipoprotein metabolism and atherosclerosis, as well as plasma PLTP activity. 
A proatherogenic role for macrophage-derived PLTP was suggested in a 
recent report (van Haperen et al., 2008). However, opposite results have also been 
published showing that macrophage-derived PLTP is atheroprotective against diet-
induced atherosclerosis in LDLr–/– mice (Valenta et al., 2006b; Valenta et al., 2008). 
The discrepancies between the results may be due to several factors: 1) the degree of 
hypercholesterolemia achieved by the atherogenic diets; 2) the time-dependency of 
the progression of atherosclerosis; 3) the genetic background and sex of the mice; 
and 4) other factors, including environmental factors as well as the time of recovery 
from irradiation (Curtiss, 2006). Thus, the differences in the experimental setups 
may have caused the opposite results and conclusions reported by us and Valenta et 
al. Furthermore, Yang et al (Yang et al., 2006) recently reported that, in mice, many 
hepatic genes show sexual dimorphism, and the largest changes (> 3-fold) in gene 
expression between females and males are observed in genes involved in steroid and 
lipid metabolism.  
 
5.3 Cholesterol efflux from macrophage foam cells is enhanced by 
active PLTP via generation of two types of acceptors (III) 
 
Exogenous PLTP has been implicated in lipid efflux (von Eckardstein et al., 1996; 
Lee et al., 2003; Oram et al., 2003), although the exact function of different forms of 
PLTP, HA-PLTP and LA-PLTP (Oka et al., 2000a; Karkkainen et al., 2002), in the 
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RCT pathway is not known. The aim of this study was to clarify the role of the two 
forms of PLTP in cholesterol efflux from cholesterol-loaded macrophages.  
5.3.1 Effect of HA-PLTP and LA-PLTP on cholesterol efflux 
For the efflux experiments, the monocytes were treated with phorbol 12-myristate-
13-acetate (PMA) to differentiate the cells into macrophages, followed by loading of 
the cells in the presence of [3H]CE-acetyl-LDL. Reportedly, acetyl-LDL-delivered 
cholesterol is preferentially transported to late endosomes and lysosomes, and this 
pool is readily accessible to apoA-I-facilitated efflux by the ABCA1-dependent 
pathway (Wang et al., 2007a). To study the effect of PLTP on cholesterol efflux 
from macrophages to HDL and apoA-I, apoE-free HDL3 and lipid-free apoA-I  were 
incubated prior to efflux for 24 h at +37°C with  i) HA-PLTP, ii) LA-PLTP or with 
iii) PBS only serving as a control. The results demonstrate that HA-PLTP increased 
preβ-HDL formation and caused a 42% increase in cholesterol efflux to HDL  
(P < 0.001), while LA-PLTP neither formed preβ-HDL nor increased cholesterol 
efflux, demonstrating that the PL transfer activity of PLTP is a prerequisite for 
enhanced cholesterol efflux from macrophages to HDL (III, Fig. 1). When lipid-free 
apoA-I was used as a cholesterol acceptor, neither HA- nor LA-PLTP were able to 
enhance cholesterol efflux to lipid-free apoA-I. PLTP alone did not induce 
cholesterol efflux, an observation that is discrepant with the observation by Oram et 
al (Oram et al., 2003). The reason for this discrepancy may be caused by the 
difference in cells used in the experiments (macrophages vs. non-macrophage cells). 
In addition to THP-1 cells, primary monocyte-derived macrophages isolated 
from human blood were used for the efflux experiments. In accordance with the 
results from THP-1 cells, increased cholesterol efflux to HDL preincubated with 
HA-PLTP was observed (P < 0.01), whereas LA-PLTP was unable to improve 
cholesterol efflux.  
5.3.2 Isolation of preβ-HDL and large fused HDL particles and their 
functionality in cholesterol efflux 
To analyze cholesterol efflux to particles generated by HA-PLTP, the HDL 
conversion products, small preβ-HDL and large fused HDL particles, were isolated 
by size-exclusion chromatography and analyzed with native gradient gel 
electrophoresis (GGE) (Pussinen et al., 1995). During HA-PLTP-facilitated 
conversion, large fused HDL particles with an apparent size of 250 kDa were 
formed. LA-PLTP had no effect on the size of HDL particles. Isolated preβ-HDL 
acted as a functional cholesterol acceptor in the efflux of cholesterol from THP-1 
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cells. Furthermore, removal of preβ-HDL by immunoprecipitation caused a 47% 
decrease in cholesterol efflux compared with the control (P < 0.001) (III, Fig. 4). 
These results demonstrate that the effect of HA-PLTP on cholesterol efflux is partly 
mediated by its ability to enhance preβ-HDL formation. 
Besides preβ-HDL, also spherical HDL particles have been shown to function 
as cholesterol acceptors (Wang et al., 2004). The large fused HDL particles 
generated by HA-PLTP were more potent cholesterol acceptors than the control 
HDL particles not treated with PLTP (P < 0.01). This observation agreed with 
previous results demonstrating  that large  spherical HDL particles as well as large
rHDL particles are more potent cholesterol acceptors than small-sized HDL particles 
(Davidson et al., 1995; Gelissen et al., 2006). The large fused HDL particles 
generated by HA-PLTP released cellular cholesterol more efficiently compared with 
the control HDL particles. Compositional analyses demonstrated that the PL and TG 
contents of these particles were slightly increased, whereas the protein content was 
lower compared with the particles not treated with HA-PLTP. The total cholesterol 
content of the particles was similar. Moreover, the relative apoE content of these 
large fused HDL particles was about 40% higher than that of the HDL particles not 
treated with PLTP. Increased HDL particle size and increased PL (Davidson et al., 
1995; Fournier et al., 1996; Fournier et al., 1997; Gelissen et al., 2006) as well as apoE 
(Matsuura et al., 2006) contents can improve the acceptor properties of the particles. 
HDL enriched with apoE can accept free cholesterol from macrophages, after which 
the cholesterol can be esterified by LCAT and delivered to the liver for excretion 
(Matsuura et al., 2006). The mechanism with which PLTP-remodeled HDL particles 
participate in the removal of cholesterol from macrophage foam cells is illustrated in 
Figure 7. 
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Figure 7. Function of PLTP-remodeled HDL particles in the removal of cholesterol 
from peripheral cells. 
 
5.4 Association of CETP with HDL particles reduces its 
proteolytic inactivation by mast cell chymase (IV) 
The human atherosclerotic intima contains several types of inflammatory cells, 
including mast cells that secrete the neutral serine protease chymase into the intimal 
fluid (Kaartinen et al., 1994; Lindstedt et al., 2004). The intimal fluid also contains 
nascent discoidal HDL particles as well as proteins that are able to modify the 
structure of HDL, such as CETP. Most of the CETP in plasma is bound to α-HDL 
particles (Marcel et al., 1990), and CETP can enter the intimal fluid from the plasma 
compartment in association with HDL particles or it can be expressed and secreted 
locally by cholesterol-loaded macrophages (Faust et al., 1990). Chymase has been 
shown to degrade PLTP, leading to reduced PL transfer activity (Lee et al., 2003). 
However, it is not known whether chymase is able to degrade CETP, its structurally 
closely related lipid transfer protein. Thus, chymase-dependent degradation of 
human CETP and CETP-HDL complexes in vitro was investigated. Furthermore, the 
effect of CETP on HDL-facilitated cholesterol efflux was studied. 
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5.4.1  Effect of chymase on CETP 
To study the effect of chymase on the proteolytic degradation and lipid transfer 
activity of CETP, CETP was incubated with recombinant human chymase, either as 
such or after complexing CETP with human lipid-free apoA-I, discoidal rHDL 
particles, HDL2, and HDL3. Incubation of lipid-free apoA-I or apoA-I-containing 
HDL with CETP leads to formation of CETP-containing complexes (Guyard-
Dangremont et al., 1994; Bruce et al., 1995). Analysis of the CETP-containing 
complexes by SDS-PAGE and immunoblotting using the CETP-specific monoclonal 
antibody (MAb) TP2 (Swenson et al., 1989) demonstrated that chymase rapidly and 
progressively degraded CETP, generating a specific proteolytic pattern of two major 
bands with approximate molecular masses of 45 and 34 kDa with a concomitant 
reduction in its CE transfer activity (IV, Fig. 1, Fig. 3). Complexation of CETP with 
lipid-free apoA-I or HDL2 rendered CETP more resistant against the proteolytic 
action of chymase. Complexes of CETP with HDL3 were also partially protected 
from degradation. In contrast, complexation with rHDL conferred on CETP the least 
resistance against chymase, and the degree of proteolysis was similar to that of free 
CETP. Furthermore, CETP activity was partially preserved when it was complexed 
with different HDL ligands. ApoA-I and HDL2 conferred the highest protection of 
CETP activity, HDL3 partially protected CETP activity, and rHDL conferred the 
lowest protection. A previous study demonstrated that two other proteases, trypsin 
and α-chymotrypsin, caused significant fragmentation of human CETP, but rendered 
its CE transfer activity (Hesler et al., 1989). As CETP activity was lowered by 
chymase, it suggests that chymase, contrary to trypsin and α-chymotrypsin, is able 
to unfold the tertiary structure of CETP, necessary for CE transfer activity. The 
crystal structure of CETP has implicated that CETP can bind a single HDL particle 
on the concave face of the CETP molecule (Qiu et al., 2007). Our observation that 
incubation of CETP with apoA-I-containing particles of various sizes and shapes led 
to the formation of complexes in which CETP was less exposed to degradation by 
chymase may indicate a deeper surface insertion of CETP in complexes with 
spherical rather than discoidal HDL particles, thus rendering the domains required 
for CE transfer less accessible to chymase. 
5.4.2 Effect of chymase on apoA-I in CETP-HDL complexes 
Since complexation of CETP with lipid-free apoA-I or apoA-I-containing particles 
generated CETP-containing complexes that protected CETP against proteolysis by 
chymase, the integrity of apoA-I in those complexes was analyzed next. Previously, 
lipid-poor apoA-I particles have been shown to serve as substrates for chymase 
(Lee-Rueckert and Kovanen, 2006). In addition to CETP, the ability of PLTP to 
 70 
 
protect lipid-free apoA-I from being proteolyzed by chymase was studied. The 
results demonstrated that the protective effect against extensive apoA-I 
fragmentation by chymase was attributed specifically to CETP, and the presence of 
PLTP did not abolish this CETP-associated protective effect. Moreover, the 
complexation with CETP efficiently protected apoA-I in rHDL particles against 
proteolysis (IV, Fig. 5). ApoA-I in the spherical HDL3 and HDL2 particles was also 
poorly degraded by chymase, and the formation of complexes with CETP had no 
further effect on such a minor degree of apoA-I degradation. Our results are in 
agreement with the previous findings that discoidal, rather than spherical HDL 
particles are the most sensitive targets of mast cell chymase (Lee et al., 1999; Lee et 
al., 2000). Here, only the effect of chymase was studied. However, apoA-I in 
discoidal HDL is susceptible to several proteases present in the intimal fluid (Lee-
Rueckert and Kovanen, 2006), and their role in apoA-I degradation needs to be 
studied. 
5.4.3 Effect of CETP on cholesterol efflux 
The role of CETP in the removal of cellular cholesterol is controversial (Zhang et 
al., 2001b; Van Eck et al., 2007). Thus, to gain more insight into the potential effect 
of CETP in this process, functional experiments with cholesterol-loaded THP-1 
macrophages were performed. Lipid-free apoA-I strongly increased cholesterol 
efflux (up to 27%), reflecting stimulation of the ABCA1 pathway, while formation 
of CETP-apoA-I complexes had no further effect. Discoidal rHDL, HDL3, and 
HDL2 all promoted similar efflux (~15%), and complexation of CETP with only 
HDL3 enhanced efflux (P = 0.0287) (IV, Fig. 6). Chymase decreased cholesterol 
efflux to all acceptors used. Indeed, the inhibitory effect of chymase was associated 
with extensive degradation of apoE, both in HDL3 and HDL2, whether complexed 
with CETP or not. Even though CETP did not modify the efflux induced by rHDL, it 
fully restored the efflux-promoting ability of the chymase-treated CETP-rHDL 
complexes. CETP alone did not affect cholesterol efflux. Our in vitro data are 
supported by recent in vivo data showing that expression of human CETP in the 
mouse liver promotes macrophage RCT by increasing cholesterol uptake by the liver 
(Tanigawa et al., 2007), confirming the importance of macrophage-derived CETP in 
protecting nascent discoidal HDL against proteolysis. 
The effect of chymase on the functional domains of apoA-I was further 
studied by Western blot analysis by using specific MAb targeted at either the N-
terminus or the C-terminal region of apoA-I. According to earlier reports, the C-
terminal sequence of apoA-I is essential for ABCA1-mediated efflux (Burgess et al., 
2002; Vedhachalam et al., 2004). Analysis of different cleavage sites in the 
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functional domains of lipid-free apoA-I and rHDL as well as their complexes with 
CETP revealed that 26-kDa polypeptide derived from proteolysis of lipid-free apoA-
I and its CETP complexes was immunoreactive against the N-terminus, whereas the 
C-terminal region of apoA-I had been cleaved off (IV, Fig. 7). In contrast, 26-kDa 
polypeptide in proteolyzed rHDL and CETP-rHDL complexes was immunoreactive 
against the C-terminal MAbs only, suggesting that cleavage had occurred at the N-
terminus. 
 
5.5 Serum, but not monocyte macrophage foam cells from low 
HDL-C subjects, displays reduced cholesterol efflux capacity 
(V) 
The aim here was to investigate whether monocyte-derived macrophages from low- 
and high-HDL subjects would display different capacities to efflux cholesterol to 
apoA-I, HDL2, or serum, and whether sera from low- and high-HDL subjects differ 
as acceptors of cholesterol from human THP-1 macrophages.  
5.5.1 Characteristics of the study subjects  
Details of the study subjects with low and high HDL-C are described in Table 1 and 
Table 2 (V). As expected, HDL-C, TC, apoA-I, and apoA-II were significantly 
higher in the high-HDL-C subjects, while the low-HDL-C subjects had significantly 
higher levels of TGs, and a bigger waist circumference and body mass index (BMI) 
than the high-HDL-C subjects. LDL-C and apoB-100 were similar in the two 
groups. In the low-HDL-C subjects, ~30% of their HDL-associated cholesterol was 
recovered in the HDL2 fraction, while in the high-HDL-C subjects, ~50% of the total 
HDL cholesterol represented HDL2. In the low-HDL-C subjects the large-sized 
particles were significantly decreased, while in the high-HDL-C subjects the large 
HDL2b particles represented the majority of HDL particles. Together, HDL2b and 
HDL2a represented ~70% of all HDL particles in the high-HDL-C subjects. 
Furthermore, the low-HDL-C subjects had smaller mean HDL particle size than did 
the high-HDL subjects. The observations regarding smaller mean HDL particle size 
and a decreased proportion of large HDL particles in low-HDL-C subjects are in 
accordance with the previous reports (Soderlund et al., 2005; Watanabe et al., 2006). 
Analysis of percent mass composition revealed that both HDL2 and HDL3 displayed 
significant enrichment of TGs in the low-HDL-C subjects. The basal level of pre-
HDL particles in the two study groups was similar. However, upon incubation in the 
presence of the LCAT inhibitor iodoacetamide, sera from the low-HDL-C subjects 
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generated higher levels of pre-HDL (as a percentage of total HDL) compared with 
the high-HDL-C group (P = 0.028).  
5.5.2 Cholesterol efflux from monocyte-derived macrophage foam cells 
isolated from the study subjects 
Human monocyte-derived macrophages were obtained from human whole blood by 
cell culturing using a granulocyte-macrophage colony-stimulating factor (GM-CSF) 
to differentiate monocytes into macrophages. The criterion used to define a 
macrophage is based on the morphology of the differentiated cells, as reported 
previously (Waldo et al., 2008). Macrophages were loaded with acetyl-LDL and 
after loading, the majority of the cholesterol was in an esterified form (average, 76 ± 
5.2% of the total cholesterol mass). Cholesterol efflux from macrophages obtained 
from low- or high- HDL-C subjects to apoA-I, HDL2, and serum was similar (V, 
Fig. 2). The present data extend the previous finding, which demonstrated similar 
cholesterol efflux to lipid-free apoA-I from macrophages derived from either low-
HDL-C subjects or control subjects (Soro-Paavonen et al., 2007).  
5.5.3 Expression of ABCA1 and ABCG1 mRNA and protein 
Transcripts of ABCA1 and ABCG1 were analyzed in cultured unloaded monocyte-
derived macrophages. The relative levels of ABCA1 and ABCG1 mRNA expression 
in monocyte macrophages did not differ between the low- and high-HDL-C subjects. 
Expression of ABCA1 and ABCG1 protein in macrophages from the low- and high-
HDL-C subjects, after the macrophages were loaded with acetyl-LDL, was also 
similar when measured by Western blot analysis (V, Fig. 3). These data imply that 
neither the ABCA1 pathway nor the ABCG1 pathway was significantly impaired, 
which is in accordance with similar efflux values observed between macrophages 
derived from low-HDL-C and high-HDL-C subjects.  
As a proinflammatory state in monocytes and monocyte-derived macrophages 
from low-HDL-C subjects was recently reported (Sarov-Blat et al., 2007), the 
inflammation status of the isolated macrophages was evaluated by analyzing the 
levels of expression of the major inflammatory genes TNF-, IL-6, and MCP-1. 
However, the levels of expression of these inflammation markers were similar in the 
low-HDL-C and high-HDL-C subjects. No significant difference was observed in 
inflammation markers between low-HDL-C subjects with or without coronary heart 
disease (CHD). Although the inflammatory status of unloaded macrophages derived from the 
low-HDL-C and high-HDL-C subjects was similar, the monocytes used in the present 
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study are differentiated into macrophages under cell culture conditions, and thus 
they may not phenotypically fully represent those present in the vessel wall in vivo.  
5.5.4 Cholesterol efflux to sera from the study subjects 
Cholesterol efflux from THP-1 foam cells to sera from the high-HDL-C subjects 
was slightly higher than that to sera from the low-HDL-C subjects (P = 0.046) 
(Figure 8). Cholesterol efflux from foam cells to individual sera showed a positive 
association with the serum percentage of pre-HDL (r = 0.626, P = 0.0001), preβ-
HDL concentration (r = 0.754, P < 0.0001), preβ-HDL concentration after 
incubation at +37°C (r = 0.486, P = 0.005), and HDL-C (r = 0.359, P = 0.040). The 
data are in accordance with the findings that ABCA1-mediated efflux is highly 
dependent on the availability of pre-HDL (Lee et al., 2003; Mweva et al., 2006), 
and the PL content of HDL is an important determinant of cholesterol efflux 
(Fournier et al., 1997; Wang et al., 2004; Gelissen et al., 2006). Pre-HDL may be 
the preferred acceptor for the concerted action of the ABCA1 and ABCG1 
pathways, leading to high efflux from THP-1 macrophages to serum with a high 
pre-HDL content. A recent report suggested that cellular cholesterol efflux 
pathways mediated by ABCA1 and SR-BI are gender-specific (Catalano et al., 
2008). This was shown to be due to the increased levels of large CE-rich HDL2 
particles that facilitate SR-BI-mediated efflux in women, and the increased preβ-
HDL levels that facilitate efflux via ABCA1 in men.  
The effect of HDL particle size on efflux capacity and the impact of large 
HDL particles on cholesterol removal were recently demonstrated (Davidson et al., 
1995; Matsuura et al., 2006; Makela et al., 2008). As high-HDL-C subjects 
demonstrated a higher proportion of large HDL2b particles, the higher efflux to the 
sera of these subjects suggests a role of the ABCG1 pathway in cholesterol removal. 
Of note, HDL2b particles have been shown to be important determinants of carotid 
atherosclerosis, evaluated as increased IMT (Watanabe et al., 2006). In the present 
study, cholesterol efflux was similar in low-HDL-C subjects with or without CHD. 
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Figure 8. Cholesterol efflux from human THP-1 macrophage foam cells to serum 
(0.5%) from low- (n = 18) and high-HDL-C (n = 15) subjects. Box plots display the 
median and the lower and upper quartiles. The open and closed circles indicate the 
data from low-HDL-C subjects with and without CHD. 
LCAT, CETP, and PLTP are all involved in the remodeling of HDL particles (Rye 
et al., 1999) and affect RCT. CETP and PLTP activities were similar between the 
two groups. Interestingly, the low-HDL-C subjects displayed significantly higher 
LCAT activity and lower PLTP mass. HA-PLTP mass differed slightly between the 
two groups, whereas the high-HDL-C subjects had significantly higher levels of LA-
PLTP, leading to significantly increased PLTP mass. An inverse relationship 
between serum total PLTP mass and CHD risk has been reported (Yatsuya et al., 
2004), although the physiological role of LA-PLTP remains unknown. ApoE is 
important in HDL formation and maturation, in hepatic uptake of HDL (Mahley and 
Rall, 2000), and in RCT (Matsuura et al., 2006). Particularly, macrophage apoE was 
shown to promote cholesterol efflux and reduce atherosclerosis (Yu et al., 2006). 
However, apoE mRNA expression levels in unloaded monocyte-derived 
macrophages, as well as serum apoE concentration, were similar between the low-
HDL-C and high-HDL-C subjects.  
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6 SUMMARY AND CONCLUSIONS 
The aim of this thesis was to clarify the importance of PLTP and CETP in the RCT 
process, i.e the transport of cholesterol from peripheral cells to the liver for 
excretion. 
First, the importance of endogenous PLTP in ABCA1-mediated cholesterol 
efflux from macrophage foam cells was demonstrated using peritoneal macrophages 
from WT and PLTP-KO mice. The uptake of cholesterol and the ability of 
macrophages to be converted into foam cells were not impaired by the genetic 
absence of PLTP. Reportedly, ABCA1 and apoA-I may interact along an 
intracellular recycling pathway. PLTP may aid apoA-I in the stabilization of 
ABCA1, and it may participate in intracellular recycling of ABCA1 by increasing 
the transfer of PLs to ABCA1, followed by phospholipidation of acceptor particles, 
such as apoA-I. This hypothesis could also explain the defective cholesterol efflux 
found in PLTP-KO foam cells. The role of PLTP in ABCA1-mediated cholesterol 
efflux was further supported by restoration of cholesterol efflux from the PLTP-KO 
foam cells after upregulation of ABCA1 by cAMP. Based on these results, 
endogenous PLTP produced by macrophages contributes to the optimal function of 
the ABCA1-mediated cholesterol efflux process. 
To further characterize the role of PLTP in the RCT process, the effect of 
externally added PLTP on cholesterol efflux from human THP-1 macrophage foam 
cells and from human monocyte-derived macrophage foam cells was investigated. 
This study demonstrated that incubation of HDL with HA-PLTP, but not LA-PLTP, 
caused a 30-40% increase in cholesterol efflux. The observed increase was due in 
part to the formation of preβ-HDL, as preβ-HDL particles generated by HA-PLTP 
served as cholesterol acceptors for the ABCA1-mediated pathway. These results, 
obtained using acetyl-LDL-loaded macrophages, are in accordance with the 
observation that the acetyl-LDL and cholesterol esters formed are stored in a pool, 
readily accessible for efflux by the ABCA1-dependent pathway. In addition to preβ-
HDL particles, large fused HDL particles enriched with PL and apoE formed by 
HA-PLTP also behaved as efficient acceptors of cholesterol, suggesting the 
involvement of the ABCG1-promoted efflux pathway. The data demonstrate that 
only HA-PLTP can enhance cholesterol efflux from macrophage foam cells, via 
formation of preβ-HDL and large fused HDL particles. 
To reveal whether the results obtained in vitro bear any relevance in vivo, a 
LDLr-/- mouse model with a selective deficiency in PLTP in macrophages was 
generated. The selective deficiency in macrophage PLTP in LDLr–/– mice i) 
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decreased the size of atherosclerotic lesions, ii) decreased the relative levels of preβ-
HDL, iii) decreased serum cholesterol and (iiii) lowered plasma PLTP activity. 
Thus, macrophage PLTP displayed a proatherogenic role in this mouse model. As 
both exogenous and endogenous PLTP in vitro increase cholesterol removal from 
macrophage foam cells, in vivo other proatherogenic properties of PLTP, probably 
related to the observed changes in plasma lipoproteins, override the antiatherogenic 
function of macrophage PLTP. Hepatic Kupffer cells express higher PLTP mRNA 
levels than do the other hepatic cell types that contribute to plasma PLTP activity. 
The results from bone marrow transplantation studies suggest that the contribution 
of PLTP to atherosclerosis is determined by a balance between lesion PLTP activity, 
which is antiatherogenic, and plasma PLTP activity, which is proatherogenic.   
To study whether PLTP also regulates cholesterol efflux from macrophage 
foam cells in humans, cholesterol efflux from monocyte macrophages derived from 
low- and high-HDL-C subjects and the ability of the sera derived from these 
subjects to function as cholesterol acceptors were determined. Monocyte 
macrophages isolated from either low- or high-HDL-C subjects displayed similar 
cholesterol efflux to apoA-I, HDL2, and whole serum. However, sera from high-
HDL-C subjects promoted higher cholesterol efflux from THP-1 macrophage foam 
cells than did sera from low-HDL-C subjects. This was most probably due to the 
higher proportion of both HDL2b and pre-HDL particles. Thus, low levels of large 
HDL particles and preβ-HDL particles may limit the serum efflux capacity and 
increase the susceptibility of low-HDL-C subjects to lesion development. No 
difference in plasma PLTP activity between the two groups was evident. 
As such, CETP, like PLTP, plays a crucial role in HDL metabolism, and a 
direct role for macrophage-derived CETP in cellular cholesterol efflux has been 
suggested. However, CETP-HDL functional interaction has not been studied in this 
process, and therefore the role of CETP in the cholesterol efflux process was 
analyzed further. Association of CETP with HDL particles protected the integrity 
and CE transfer function of CETP as well as the structure of associated apoA-I 
against the proteolytic effects of chymase. Spherical HDL particles conferred the 
highest protection against chymase to CETP, whereas CETP protected discoidal 
HDL particles against chymase-mediated proteolysis. Formation of CETP-HDL 
complexes was not able to prevent a decrease in cholesterol efflux to mature HDL 
particles, whereas CETP-rHDL complexes remained functional in cholesterol efflux 
in spite of chymase treatment. This suggests that the association of CETP with 
rHDL prevents chymase-dependent functional inactivation of discoidal rHDL by 
preserving apoA-I intactness. The protective function of CETP against chymase 
could be of significance, as the relative concentration of nascent discoidal HDL 
particles in the intimal fluid is relatively high. 
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